HRP20020808A2 - Benzoamide piperidine containing compounds and related compounds - Google Patents

Info

Publication number

HRP20020808A2

HRP20020808A2 HRP20020808A HRP20020808A2 HR P20020808 A2 HRP20020808 A2 HR P20020808A2 HR P20020808 A HRP20020808 A HR P20020808A HR P20020808 A2 HRP20020808 A2 HR P20020808A2

Authority

HR

Croatia

Prior art keywords

methyl

methoxy

phenylpiperidin

ylamino

phenyl

Prior art date

2000-04-10

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims description 387
• NXUSCSCBRVCRCN-UHFFFAOYSA-N benzamide;piperidine Chemical compound C1CCNCC1.NC(=O)C1=CC=CC=C1 NXUSCSCBRVCRCN-UHFFFAOYSA-N 0.000 title description 2
• -1 phenyl-(C1-C3)alkoxy Chemical group 0.000 claims description 237
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 157
• 125000001153 fluoro group Chemical group F* 0.000 claims description 140
• 125000001424 substituent group Chemical group 0.000 claims description 129
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 119
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 114
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 101
• 208000035475 disorder Diseases 0.000 claims description 93
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 67
• 229910052739 hydrogen Inorganic materials 0.000 claims description 63
• 239000001257 hydrogen Substances 0.000 claims description 63
• 125000000623 heterocyclic group Chemical group 0.000 claims description 59
• 150000003839 salts Chemical class 0.000 claims description 59
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 58
• 238000000034 method Methods 0.000 claims description 58
• 229910052736 halogen Inorganic materials 0.000 claims description 56
• 150000002367 halogens Chemical class 0.000 claims description 54
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 51
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 50
• 229910052757 nitrogen Inorganic materials 0.000 claims description 43
• 241000124008 Mammalia Species 0.000 claims description 41
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 41
• 229910052799 carbon Inorganic materials 0.000 claims description 39
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 38
• 208000002193 Pain Diseases 0.000 claims description 30
• 229920006395 saturated elastomer Polymers 0.000 claims description 30
• 125000004043 oxo group Chemical group O=* 0.000 claims description 28
• 229910052760 oxygen Inorganic materials 0.000 claims description 28
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 28
• 239000000203 mixture Substances 0.000 claims description 27
• 208000028017 Psychotic disease Diseases 0.000 claims description 24
• 125000000217 alkyl group Chemical group 0.000 claims description 24
• 208000019901 Anxiety disease Diseases 0.000 claims description 23
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 23
• 150000001412 amines Chemical class 0.000 claims description 22
• 125000005842 heteroatom Chemical group 0.000 claims description 22
• 229910052717 sulfur Inorganic materials 0.000 claims description 22
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
• 208000020401 Depressive disease Diseases 0.000 claims description 20
• 125000004432 carbon atom Chemical group C* 0.000 claims description 20
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 19
• 239000005977 Ethylene Substances 0.000 claims description 19
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 19
• 239000003814 drug Substances 0.000 claims description 19
• 239000001301 oxygen Substances 0.000 claims description 19
• 125000002837 carbocyclic group Chemical group 0.000 claims description 18
• 201000010099 disease Diseases 0.000 claims description 18
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 17
• 206010047700 Vomiting Diseases 0.000 claims description 17
• 239000003937 drug carrier Substances 0.000 claims description 17
• 150000002431 hydrogen Chemical group 0.000 claims description 17
• 239000011593 sulfur Substances 0.000 claims description 17
• 101100134929 Gallus gallus COR9 gene Chemical group 0.000 claims description 15
• 230000036506 anxiety Effects 0.000 claims description 15
• 239000008194 pharmaceutical composition Substances 0.000 claims description 14
• 208000001640 Fibromyalgia Diseases 0.000 claims description 13
• 125000004104 aryloxy group Chemical group 0.000 claims description 13
• 125000005553 heteroaryloxy group Chemical group 0.000 claims description 13
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 12
• 208000020925 Bipolar disease Diseases 0.000 claims description 12
• 206010012218 Delirium Diseases 0.000 claims description 12
• 208000023105 Huntington disease Diseases 0.000 claims description 12
• 206010020751 Hypersensitivity Diseases 0.000 claims description 12
• 208000019022 Mood disease Diseases 0.000 claims description 12
• 208000016285 Movement disease Diseases 0.000 claims description 12
• 208000018737 Parkinson disease Diseases 0.000 claims description 12
• 230000001154 acute effect Effects 0.000 claims description 12
• 235000014632 disordered eating Nutrition 0.000 claims description 12
• 208000024732 dysthymic disease Diseases 0.000 claims description 12
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
• 125000005647 linker group Chemical group 0.000 claims description 12
• 208000024714 major depressive disease Diseases 0.000 claims description 12
• 239000003176 neuroleptic agent Substances 0.000 claims description 12
• 230000000701 neuroleptic effect Effects 0.000 claims description 12
• 208000015238 neurotic disease Diseases 0.000 claims description 12
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 12
• 125000004076 pyridyl group Chemical group 0.000 claims description 12
• 125000004434 sulfur atom Chemical group 0.000 claims description 12
• 206010012289 Dementia Diseases 0.000 claims description 11
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 11
• 238000002512 chemotherapy Methods 0.000 claims description 11
• 229940079593 drug Drugs 0.000 claims description 11
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
• 208000027691 Conduct disease Diseases 0.000 claims description 10
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 10
• 241000725303 Human immunodeficiency virus Species 0.000 claims description 10
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 10
• 125000004429 atom Chemical group 0.000 claims description 10
• 229910052731 fluorine Inorganic materials 0.000 claims description 10
• 239000011737 fluorine Substances 0.000 claims description 10
• 230000002496 gastric effect Effects 0.000 claims description 10
• 206010027599 migraine Diseases 0.000 claims description 10
• 208000004296 neuralgia Diseases 0.000 claims description 10
• 125000002971 oxazolyl group Chemical group 0.000 claims description 10
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 10
• 125000000335 thiazolyl group Chemical group 0.000 claims description 10
• 208000024827 Alzheimer disease Diseases 0.000 claims description 9
• 208000030814 Eating disease Diseases 0.000 claims description 9
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 9
• 239000002249 anxiolytic agent Substances 0.000 claims description 9
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 9
• ZCUCBZOOHSWZBO-UHFFFAOYSA-N 6-methoxy-3-methyl-5-[[(6-methyl-2-phenylpiperidin-3-yl)amino]methyl]-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one Chemical compound COC1=CC=2C3CC3C(=O)N(C)C=2C=C1CNC1CCC(C)NC1C1=CC=CC=C1 ZCUCBZOOHSWZBO-UHFFFAOYSA-N 0.000 claims description 8
• 208000008811 Agoraphobia Diseases 0.000 claims description 8
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
• 206010010741 Conjunctivitis Diseases 0.000 claims description 8
• 201000004624 Dermatitis Diseases 0.000 claims description 8
• 208000018522 Gastrointestinal disease Diseases 0.000 claims description 8
• 206010020853 Hypertonic bladder Diseases 0.000 claims description 8
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
• 206010028980 Neoplasm Diseases 0.000 claims description 8
• 230000007815 allergy Effects 0.000 claims description 8
• 208000028683 bipolar I disease Diseases 0.000 claims description 8
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 8
• 230000035987 intoxication Effects 0.000 claims description 8
• 231100000566 intoxication Toxicity 0.000 claims description 8
• 125000002950 monocyclic group Chemical group 0.000 claims description 8
• 201000006417 multiple sclerosis Diseases 0.000 claims description 8
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
• 125000003003 spiro group Chemical group 0.000 claims description 8
• 208000011117 substance-related disease Diseases 0.000 claims description 8
• 230000008673 vomiting Effects 0.000 claims description 8
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 7
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 7
• 208000006673 asthma Diseases 0.000 claims description 7
• 230000003542 behavioural effect Effects 0.000 claims description 7
• 230000006378 damage Effects 0.000 claims description 7
• 229940005483 opioid analgesics Drugs 0.000 claims description 7
• 201000008482 osteoarthritis Diseases 0.000 claims description 7
• 210000002345 respiratory system Anatomy 0.000 claims description 7
• 229910052721 tungsten Inorganic materials 0.000 claims description 7
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
• 206010046543 Urinary incontinence Diseases 0.000 claims description 6
• 229910052794 bromium Inorganic materials 0.000 claims description 6
• 230000001684 chronic effect Effects 0.000 claims description 6
• 206010012601 diabetes mellitus Diseases 0.000 claims description 6
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
• 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
• 206010006458 Bronchitis chronic Diseases 0.000 claims description 5
• 208000000094 Chronic Pain Diseases 0.000 claims description 5
• 241000590002 Helicobacter pylori Species 0.000 claims description 5
• 206010064921 Urinary tract inflammation Diseases 0.000 claims description 5
• 230000033115 angiogenesis Effects 0.000 claims description 5
• 230000000949 anxiolytic effect Effects 0.000 claims description 5
• 229940005530 anxiolytics Drugs 0.000 claims description 5
• 125000002619 bicyclic group Chemical group 0.000 claims description 5
• 206010006451 bronchitis Diseases 0.000 claims description 5
• 208000007451 chronic bronchitis Diseases 0.000 claims description 5
• 201000003146 cystitis Diseases 0.000 claims description 5
• 206010061428 decreased appetite Diseases 0.000 claims description 5
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
• 208000030533 eye disease Diseases 0.000 claims description 5
• 208000027866 inflammatory disease Diseases 0.000 claims description 5
• 208000027232 peripheral nervous system disease Diseases 0.000 claims description 5
• 208000011580 syndromic disease Diseases 0.000 claims description 5
• 206010044652 trigeminal neuralgia Diseases 0.000 claims description 5
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 4
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
• KAMAILFXGOVKBC-UHFFFAOYSA-N 5-methoxy-1,3,3-trimethyl-6-[[(2-phenylpiperidin-3-yl)amino]methyl]pyrrolo[3,2-b]pyridin-2-one Chemical compound COC1=NC(C(C(=O)N2C)(C)C)=C2C=C1CNC1CCCNC1C1=CC=CC=C1 KAMAILFXGOVKBC-UHFFFAOYSA-N 0.000 claims description 4
• SNHDVCVCJRZBFX-UHFFFAOYSA-N 6-methoxy-1,3,3-trimethyl-5-[[(2-phenyl-1-propan-2-ylpiperidin-3-yl)amino]methyl]indol-2-one Chemical compound COC1=CC=2N(C)C(=O)C(C)(C)C=2C=C1CNC1CCCN(C(C)C)C1C1=CC=CC=C1 SNHDVCVCJRZBFX-UHFFFAOYSA-N 0.000 claims description 4
• HEMSXMUFDIZIMX-UHFFFAOYSA-N 6-methoxy-1,3,3-trimethyl-5-[[(2-phenylpiperidin-3-yl)amino]methyl]pyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=NC=2N(C)C(=O)C(C)(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 HEMSXMUFDIZIMX-UHFFFAOYSA-N 0.000 claims description 4
• PZROMZSDSNGSCA-UHFFFAOYSA-N 6-methoxy-1-methyl-7-(10-phenyl-1,9-diazaspiro[4.5]decan-3-yl)-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1C(C1)CNC21CCCNC2C1=CC=CC=C1 PZROMZSDSNGSCA-UHFFFAOYSA-N 0.000 claims description 4
• RBTBOOLQIXDPHX-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-phenyl-6-propylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound N1C(CCC)CCC(NCC=2C(=CC=3CCC(=O)N(C)C=3C=2)OC)C1C1=CC=CC=C1 RBTBOOLQIXDPHX-UHFFFAOYSA-N 0.000 claims description 4
• NVWIXWCMNWGGOU-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydro-1,5-naphthyridin-2-one Chemical compound COC1=NC=2CCC(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 NVWIXWCMNWGGOU-UHFFFAOYSA-N 0.000 claims description 4
• WENUKNPSDNCTQJ-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(6-methyl-2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCC(C)NC1C1=CC=CC=C1 WENUKNPSDNCTQJ-UHFFFAOYSA-N 0.000 claims description 4
• BKCCDADLYSLVHI-UHFFFAOYSA-N 7-[[(6-ethyl-2-phenylpiperidin-3-yl)amino]methyl]-6-methoxy-1-methyl-3,4-dihydroquinolin-2-one Chemical compound N1C(CC)CCC(NCC=2C(=CC=3CCC(=O)N(C)C=3C=2)OC)C1C1=CC=CC=C1 BKCCDADLYSLVHI-UHFFFAOYSA-N 0.000 claims description 4
• 206010001541 Akinesia Diseases 0.000 claims description 4
• 206010002383 Angina Pectoris Diseases 0.000 claims description 4
• 206010002650 Anorexia nervosa and bulimia Diseases 0.000 claims description 4
• 208000036487 Arthropathies Diseases 0.000 claims description 4
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
• 208000020706 Autistic disease Diseases 0.000 claims description 4
• 206010048962 Brain oedema Diseases 0.000 claims description 4
• 208000026310 Breast neoplasm Diseases 0.000 claims description 4
• 208000021465 Brief psychotic disease Diseases 0.000 claims description 4
• 208000009079 Bronchial Spasm Diseases 0.000 claims description 4
• 208000014181 Bronchial disease Diseases 0.000 claims description 4
• 201000004813 Bronchopneumonia Diseases 0.000 claims description 4
• 206010006482 Bronchospasm Diseases 0.000 claims description 4
• 241000218236 Cannabis Species 0.000 claims description 4
• 206010008334 Cervicobrachial syndrome Diseases 0.000 claims description 4
• 206010008748 Chorea Diseases 0.000 claims description 4
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 4
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
• 208000027932 Collagen disease Diseases 0.000 claims description 4
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 4
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
• 208000011231 Crohn disease Diseases 0.000 claims description 4
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
• 102000004127 Cytokines Human genes 0.000 claims description 4
• 108090000695 Cytokines Proteins 0.000 claims description 4
• 208000024254 Delusional disease Diseases 0.000 claims description 4
• 208000016192 Demyelinating disease Diseases 0.000 claims description 4
• 206010012335 Dependence Diseases 0.000 claims description 4
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
• 206010012442 Dermatitis contact Diseases 0.000 claims description 4
• 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims description 4
• 201000010374 Down Syndrome Diseases 0.000 claims description 4
• 208000012661 Dyskinesia Diseases 0.000 claims description 4
• 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 4
• 208000010228 Erectile Dysfunction Diseases 0.000 claims description 4
• 206010015866 Extravasation Diseases 0.000 claims description 4
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
• 208000001613 Gambling Diseases 0.000 claims description 4
• 208000007882 Gastritis Diseases 0.000 claims description 4
• 208000031886 HIV Infections Diseases 0.000 claims description 4
• 208000004547 Hallucinations Diseases 0.000 claims description 4
• 206010019196 Head injury Diseases 0.000 claims description 4
• 206010049949 Intercostal neuralgia Diseases 0.000 claims description 4
• 206010022998 Irritability Diseases 0.000 claims description 4
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
• 208000012659 Joint disease Diseases 0.000 claims description 4
• 206010025323 Lymphomas Diseases 0.000 claims description 4
• 206010026749 Mania Diseases 0.000 claims description 4
• 208000026139 Memory disease Diseases 0.000 claims description 4
• 208000036626 Mental retardation Diseases 0.000 claims description 4
• 206010053236 Mixed incontinence Diseases 0.000 claims description 4
• 208000007101 Muscle Cramp Diseases 0.000 claims description 4
• 201000005625 Neuroleptic malignant syndrome Diseases 0.000 claims description 4
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
• 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 4
• 206010033799 Paralysis Diseases 0.000 claims description 4
• 208000027089 Parkinsonian disease Diseases 0.000 claims description 4
• 206010034010 Parkinsonism Diseases 0.000 claims description 4
• 206010034912 Phobia Diseases 0.000 claims description 4
• 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
• 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 4
• 206010073211 Postural tremor Diseases 0.000 claims description 4
• 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims description 4
• 206010036618 Premenstrual syndrome Diseases 0.000 claims description 4
• 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 4
• 208000003251 Pruritus Diseases 0.000 claims description 4
• 201000004681 Psoriasis Diseases 0.000 claims description 4
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
• 208000001431 Psychomotor Agitation Diseases 0.000 claims description 4
• 206010037213 Psychomotor retardation Diseases 0.000 claims description 4
• 208000027465 Psychotic Affective disease Diseases 0.000 claims description 4
• 208000003782 Raynaud disease Diseases 0.000 claims description 4
• 208000012322 Raynaud phenomenon Diseases 0.000 claims description 4
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 4
• 208000033464 Reiter syndrome Diseases 0.000 claims description 4
• 206010038743 Restlessness Diseases 0.000 claims description 4
• 206010038934 Retinopathy proliferative Diseases 0.000 claims description 4
• 208000025747 Rheumatic disease Diseases 0.000 claims description 4
• 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims description 4
• 206010039710 Scleroderma Diseases 0.000 claims description 4
• 208000034189 Sclerosis Diseases 0.000 claims description 4
• 201000000552 Scott syndrome Diseases 0.000 claims description 4
• 206010039966 Senile dementia Diseases 0.000 claims description 4
• 201000001880 Sexual dysfunction Diseases 0.000 claims description 4
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 4
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
• 206010041250 Social phobia Diseases 0.000 claims description 4
• 208000005392 Spasm Diseases 0.000 claims description 4
• 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 4
• 208000013200 Stress disease Diseases 0.000 claims description 4
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 4
• 206010042496 Sunburn Diseases 0.000 claims description 4
• 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 4
• 206010068932 Terminal insomnia Diseases 0.000 claims description 4
• 208000000323 Tourette Syndrome Diseases 0.000 claims description 4
• 208000016620 Tourette disease Diseases 0.000 claims description 4
• 241000159243 Toxicodendron radicans Species 0.000 claims description 4
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 4
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
• 208000000921 Urge Urinary Incontinence Diseases 0.000 claims description 4
• 208000024780 Urticaria Diseases 0.000 claims description 4
• 201000004810 Vascular dementia Diseases 0.000 claims description 4
• 210000000683 abdominal cavity Anatomy 0.000 claims description 4
• 208000005298 acute pain Diseases 0.000 claims description 4
• 208000012826 adjustment disease Diseases 0.000 claims description 4
• 230000002411 adverse Effects 0.000 claims description 4
• 239000000443 aerosol Substances 0.000 claims description 4
• 208000026935 allergic disease Diseases 0.000 claims description 4
• 201000002426 animal phobia Diseases 0.000 claims description 4
• 208000022531 anorexia Diseases 0.000 claims description 4
• 201000008937 atopic dermatitis Diseases 0.000 claims description 4
• 208000010668 atopic eczema Diseases 0.000 claims description 4
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
• 208000025748 atypical depressive disease Diseases 0.000 claims description 4
• 230000006399 behavior Effects 0.000 claims description 4
• 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 4
• 208000022257 bipolar II disease Diseases 0.000 claims description 4
• 230000017531 blood circulation Effects 0.000 claims description 4
• 208000030963 borderline personality disease Diseases 0.000 claims description 4
• 208000006752 brain edema Diseases 0.000 claims description 4
• 229960001948 caffeine Drugs 0.000 claims description 4
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
• 230000004663 cell proliferation Effects 0.000 claims description 4
• 230000002490 cerebral effect Effects 0.000 claims description 4
• 206010008118 cerebral infarction Diseases 0.000 claims description 4
• 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
• 229960003920 cocaine Drugs 0.000 claims description 4
• 208000010877 cognitive disease Diseases 0.000 claims description 4
• 230000001149 cognitive effect Effects 0.000 claims description 4
• 208000010247 contact dermatitis Diseases 0.000 claims description 4
• 208000026725 cyclothymic disease Diseases 0.000 claims description 4
• 208000010118 dystonia Diseases 0.000 claims description 4
• 206010015037 epilepsy Diseases 0.000 claims description 4
• 230000036251 extravasation Effects 0.000 claims description 4
• 230000006870 function Effects 0.000 claims description 4
• 206010017758 gastric cancer Diseases 0.000 claims description 4
• 208000010749 gastric carcinoma Diseases 0.000 claims description 4
• 201000011587 gastric lymphoma Diseases 0.000 claims description 4
• 239000000380 hallucinogen Substances 0.000 claims description 4
• 229940037467 helicobacter pylori Drugs 0.000 claims description 4
• 230000009610 hypersensitivity Effects 0.000 claims description 4
• 206010020765 hypersomnia Diseases 0.000 claims description 4
• 239000003326 hypnotic agent Substances 0.000 claims description 4
• 230000000147 hypnotic effect Effects 0.000 claims description 4
• 230000008105 immune reaction Effects 0.000 claims description 4
• 230000036039 immunity Effects 0.000 claims description 4
• 201000001881 impotence Diseases 0.000 claims description 4
• 208000015181 infectious disease Diseases 0.000 claims description 4
• 230000002757 inflammatory effect Effects 0.000 claims description 4
• 206010022437 insomnia Diseases 0.000 claims description 4
• 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 4
• 201000003995 melancholia Diseases 0.000 claims description 4
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
• 210000003097 mucus Anatomy 0.000 claims description 4
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 4
• 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 4
• 230000003767 neural control Effects 0.000 claims description 4
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
• 208000037860 neuroleptic-induced Akathisia Diseases 0.000 claims description 4
• 201000001119 neuropathy Diseases 0.000 claims description 4
• 230000007823 neuropathy Effects 0.000 claims description 4
• 208000025319 neurotic depression Diseases 0.000 claims description 4
• 229960002715 nicotine Drugs 0.000 claims description 4
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 4
• 210000000056 organ Anatomy 0.000 claims description 4
• 208000020629 overactive bladder Diseases 0.000 claims description 4
• 208000019906 panic disease Diseases 0.000 claims description 4
• 208000002851 paranoid schizophrenia Diseases 0.000 claims description 4
• 208000013667 paroxysmal dyskinesia Diseases 0.000 claims description 4
• 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
• 206010036596 premature ejaculation Diseases 0.000 claims description 4
• 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 4
• 239000003380 propellant Substances 0.000 claims description 4
• 208000002574 reactive arthritis Diseases 0.000 claims description 4
• 230000000306 recurrent effect Effects 0.000 claims description 4
• 230000011514 reflex Effects 0.000 claims description 4
• 206010039083 rhinitis Diseases 0.000 claims description 4
• 201000000980 schizophrenia Diseases 0.000 claims description 4
• 208000012672 seasonal affective disease Diseases 0.000 claims description 4
• 230000028327 secretion Effects 0.000 claims description 4
• 229940125723 sedative agent Drugs 0.000 claims description 4
• 239000000932 sedative agent Substances 0.000 claims description 4
• 231100000872 sexual dysfunction Toxicity 0.000 claims description 4
• 208000017520 skin disease Diseases 0.000 claims description 4
• 208000000649 small cell carcinoma Diseases 0.000 claims description 4
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
• 230000000392 somatic effect Effects 0.000 claims description 4
• 201000001716 specific phobia Diseases 0.000 claims description 4
• 201000000498 stomach carcinoma Diseases 0.000 claims description 4
• 230000035882 stress Effects 0.000 claims description 4
• 208000022170 stress incontinence Diseases 0.000 claims description 4
• 239000000126 substance Substances 0.000 claims description 4
• 239000000758 substrate Substances 0.000 claims description 4
• 230000002889 sympathetic effect Effects 0.000 claims description 4
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
• 206010046494 urge incontinence Diseases 0.000 claims description 4
• 208000019553 vascular disease Diseases 0.000 claims description 4
• 230000024883 vasodilation Effects 0.000 claims description 4
• 230000002455 vasospastic effect Effects 0.000 claims description 4
• 208000016261 weight loss Diseases 0.000 claims description 4
• 230000004580 weight loss Effects 0.000 claims description 4
• NEMMKWIXGZBNGM-UHFFFAOYSA-N 1,3,3-trimethyl-5-[[(2-phenyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-yl)amino]methyl]-6-propan-2-yloxyindol-2-one Chemical compound CC(C)OC1=CC=2N(C)C(=O)C(C)(C)C=2C=C1CNC1C2CCCC2NC1C1=CC=CC=C1 NEMMKWIXGZBNGM-UHFFFAOYSA-N 0.000 claims description 3
• YJMBEVOWHZOWHA-UHFFFAOYSA-N 6-methoxy-3-methyl-5-[[(5-methyl-2-phenylpiperidin-3-yl)amino]methyl]-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one Chemical compound COC1=CC=2C3CC3C(=O)N(C)C=2C=C1CNC1CC(C)CNC1C1=CC=CC=C1 YJMBEVOWHZOWHA-UHFFFAOYSA-N 0.000 claims description 3
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
• 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
• GXIFPPFQXPIEKY-QMMLZNLJSA-N (1r,4s,5s)-n-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-5-phenyl-8-azabicyclo[3.2.1]octan-4-amine Chemical compound N([C@@H]1[C@]2(CC[C@](N2)(CC1)[H])C=1C=CC=CC=1)CC1=CC(OC(F)(F)F)=CC=C1OC GXIFPPFQXPIEKY-QMMLZNLJSA-N 0.000 claims description 2
• SEFGIUHQMDXQON-YNEHKIRRSA-N (1s,4r,5r)-5-phenyl-8-azabicyclo[3.2.1]octan-4-amine Chemical compound C1([C@@]23CC[C@@](N2)(CC[C@H]3N)[H])=CC=CC=C1 SEFGIUHQMDXQON-YNEHKIRRSA-N 0.000 claims description 2
• GXIFPPFQXPIEKY-IOMROCGXSA-N (1s,4r,5r)-n-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-5-phenyl-8-azabicyclo[3.2.1]octan-4-amine Chemical compound N([C@H]1[C@@]2(CC[C@@](N2)(CC1)[H])C=1C=CC=CC=1)CC1=CC(OC(F)(F)F)=CC=C1OC GXIFPPFQXPIEKY-IOMROCGXSA-N 0.000 claims description 2
• YXOCELGJOBHHSV-JHJVBQTASA-N (2r,3r,6r)-6-ethyl-2-phenylpiperidin-3-amine Chemical compound N1[C@H](CC)CC[C@@H](N)[C@H]1C1=CC=CC=C1 YXOCELGJOBHHSV-JHJVBQTASA-N 0.000 claims description 2
• RIRLOSAVSUPMQW-YUSALJHKSA-N (2r,3r,6r)-6-methyl-2-phenylpiperidin-3-amine Chemical compound N1[C@H](C)CC[C@@H](N)[C@H]1C1=CC=CC=C1 RIRLOSAVSUPMQW-YUSALJHKSA-N 0.000 claims description 2
• YXOCELGJOBHHSV-AVGNSLFASA-N (2s,3s,6s)-6-ethyl-2-phenylpiperidin-3-amine Chemical compound N1[C@@H](CC)CC[C@H](N)[C@@H]1C1=CC=CC=C1 YXOCELGJOBHHSV-AVGNSLFASA-N 0.000 claims description 2
• RIRLOSAVSUPMQW-DLOVCJGASA-N (2s,3s,6s)-6-methyl-2-phenylpiperidin-3-amine Chemical compound N1[C@@H](C)CC[C@H](N)[C@@H]1C1=CC=CC=C1 RIRLOSAVSUPMQW-DLOVCJGASA-N 0.000 claims description 2
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
• MULPOSKRFZQFLE-UHFFFAOYSA-N 1-(2-imidazol-1-ylethyl)-n-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)N(CCN2C=NC=C2)CCC1 MULPOSKRFZQFLE-UHFFFAOYSA-N 0.000 claims description 2
• AXAQWSFGLFRZBD-UHFFFAOYSA-N 1-(2-methoxyethyl)-n-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound C=1C=CC=CC=1C1N(CCOC)CCCC1NCC1=CC(OC(F)(F)F)=CC=C1OC AXAQWSFGLFRZBD-UHFFFAOYSA-N 0.000 claims description 2
• YAJWYSJELSJMKT-UHFFFAOYSA-N 1-[2-(dimethylamino)ethyl]-n-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)N(CCN(C)C)CCC1 YAJWYSJELSJMKT-UHFFFAOYSA-N 0.000 claims description 2
• AHCHPHDMQBYYFP-UHFFFAOYSA-N 1-[2-[[(2-phenylpiperidin-3-yl)amino]methyl]phenyl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC=CC=C1CNC1C(C=2C=CC=CC=2)NCCC1 AHCHPHDMQBYYFP-UHFFFAOYSA-N 0.000 claims description 2
• LLSNSOSPXMOTPG-UHFFFAOYSA-N 1-[3-[[2-methoxy-5-(trifluoromethoxy)phenyl]methylamino]-2-phenylpiperidin-1-yl]-2-pyridin-2-ylethanone Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)N(C(=O)CC=2N=CC=CC=2)CCC1 LLSNSOSPXMOTPG-UHFFFAOYSA-N 0.000 claims description 2
• HKBYVBBMBSHRFI-UHFFFAOYSA-N 1-[3-[[2-methoxy-5-(trifluoromethoxy)phenyl]methylamino]-2-phenylpiperidin-1-yl]-2-pyridin-3-ylethanone Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)N(C(=O)CC=2C=NC=CC=2)CCC1 HKBYVBBMBSHRFI-UHFFFAOYSA-N 0.000 claims description 2
• XKBZUPBFTZJPCN-UHFFFAOYSA-N 1-[3-[[2-methoxy-5-(trifluoromethoxy)phenyl]methylamino]-2-phenylpiperidin-1-yl]-2-pyridin-4-ylethanone Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)N(C(=O)CC=2C=CN=CC=2)CCC1 XKBZUPBFTZJPCN-UHFFFAOYSA-N 0.000 claims description 2
• VUBNODWJXRHSMO-UHFFFAOYSA-N 1-[3-[[2-methoxy-5-(trifluoromethoxy)phenyl]methylamino]-2-phenylpiperidin-1-yl]-2-pyrrolidin-1-ylethanone Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)N(C(=O)CN2CCCC2)CCC1 VUBNODWJXRHSMO-UHFFFAOYSA-N 0.000 claims description 2
• JWVPMGBXKRXNPD-UHFFFAOYSA-N 1-ethyl-6-methoxy-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound C1=C2N(CC)C(=O)CCC2=CC(OC)=C1CNC1CCCNC1C1=CC=CC=C1 JWVPMGBXKRXNPD-UHFFFAOYSA-N 0.000 claims description 2
• RPIIWVPDSBEFHQ-UHFFFAOYSA-N 1-methyl-6-[[(2-phenylpiperidin-3-yl)amino]methyl]-7-propan-2-yloxy-3,4-dihydroquinolin-2-one Chemical compound CC(C)OC1=CC=2N(C)C(=O)CCC=2C=C1CNC1CCCNC1C1=CC=CC=C1 RPIIWVPDSBEFHQ-UHFFFAOYSA-N 0.000 claims description 2
• UOJSEUOILIAENP-UHFFFAOYSA-N 10-phenyl-3-[2-phenylmethoxy-5-(trifluoromethoxy)phenyl]-1-oxa-9-azaspiro[4.5]decane Chemical compound C1OC2(C(NCCC2)C=2C=CC=CC=2)CC1C1=CC(OC(F)(F)F)=CC=C1OCC1=CC=CC=C1 UOJSEUOILIAENP-UHFFFAOYSA-N 0.000 claims description 2
• LISSTSRROGYLPB-UHFFFAOYSA-N 2-(dimethylamino)-1-[3-[[2-methoxy-5-(trifluoromethoxy)phenyl]methylamino]-2-phenylpiperidin-1-yl]ethanone Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)N(C(=O)CN(C)C)CCC1 LISSTSRROGYLPB-UHFFFAOYSA-N 0.000 claims description 2
• RXJIPKUTMSXSRW-UHFFFAOYSA-N 2-imidazol-1-yl-1-[3-[[2-methoxy-5-(trifluoromethoxy)phenyl]methylamino]-2-phenylpiperidin-1-yl]ethanone Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)N(C(=O)CN2C=NC=C2)CCC1 RXJIPKUTMSXSRW-UHFFFAOYSA-N 0.000 claims description 2
• KMXAJBNVGPDDEO-UHFFFAOYSA-N 2-methoxy-5-methyl-6-oxo-7,8-dihydro-1,5-naphthyridine-3-carbaldehyde Chemical compound C1CC(=O)N(C)C2=C1N=C(OC)C(C=O)=C2 KMXAJBNVGPDDEO-UHFFFAOYSA-N 0.000 claims description 2
• KKHBISCYNNUZNO-UHFFFAOYSA-N 2-phenyl-5-propylpiperidin-3-amine Chemical compound NC1CC(CCC)CNC1C1=CC=CC=C1 KKHBISCYNNUZNO-UHFFFAOYSA-N 0.000 claims description 2
• OONVVGZQFIMALF-UHFFFAOYSA-N 2-phenyl-n-(quinoxalin-2-ylmethyl)piperidin-3-amine Chemical compound C=1N=C2C=CC=CC2=NC=1CNC1CCCNC1C1=CC=CC=C1 OONVVGZQFIMALF-UHFFFAOYSA-N 0.000 claims description 2
• UCTSVZQGTUZYLP-UHFFFAOYSA-N 2-phenyl-n-(thiophen-2-ylmethyl)piperidin-3-amine Chemical compound C=1C=CSC=1CNC1CCCNC1C1=CC=CC=C1 UCTSVZQGTUZYLP-UHFFFAOYSA-N 0.000 claims description 2
• QGYGRSDDAGEESM-UHFFFAOYSA-N 2-phenyl-n-(thiophen-3-ylmethyl)piperidin-3-amine Chemical compound C1=CSC=C1CNC1CCCNC1C1=CC=CC=C1 QGYGRSDDAGEESM-UHFFFAOYSA-N 0.000 claims description 2
• JMPDQVLLKSRLOS-UHFFFAOYSA-N 2-phenyl-n-[(3-pyridin-2-yloxyphenyl)methyl]piperidin-3-amine Chemical compound C=1C=CC(OC=2N=CC=CC=2)=CC=1CNC1CCCNC1C1=CC=CC=C1 JMPDQVLLKSRLOS-UHFFFAOYSA-N 0.000 claims description 2
• UEXKTMCOJRYCCT-UHFFFAOYSA-N 3-[2-cyclopropyloxy-5-(trifluoromethoxy)phenyl]-10-phenyl-1-oxa-9-azaspiro[4.5]decane Chemical compound C1OC2(C(NCCC2)C=2C=CC=CC=2)CC1C1=CC(OC(F)(F)F)=CC=C1OC1CC1 UEXKTMCOJRYCCT-UHFFFAOYSA-N 0.000 claims description 2
• YEZSOEXNHHSEHF-UHFFFAOYSA-N 3-methoxy-8-methyl-7-oxo-5,6-dihydro-1,8-naphthyridine-2-carbaldehyde Chemical compound C1CC(=O)N(C)C2=C1C=C(OC)C(C=O)=N2 YEZSOEXNHHSEHF-UHFFFAOYSA-N 0.000 claims description 2
• AHPASIDCSMOOAM-UHFFFAOYSA-N 5,5-diethyl-2-phenylpiperidin-3-amine Chemical compound NC1CC(CC)(CC)CNC1C1=CC=CC=C1 AHPASIDCSMOOAM-UHFFFAOYSA-N 0.000 claims description 2
• PLYVKESHJHRHKL-UHFFFAOYSA-N 5,5-dimethyl-2-phenylpiperidin-3-amine Chemical compound NC1CC(C)(C)CNC1C1=CC=CC=C1 PLYVKESHJHRHKL-UHFFFAOYSA-N 0.000 claims description 2
• GXITYMDMOJCBSQ-UHFFFAOYSA-N 5-(dimethoxymethyl)-6-methoxy-3-methyl-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one Chemical compound CN1C(=O)C2CC2C2=C1C=C(C(OC)OC)C(OC)=C2 GXITYMDMOJCBSQ-UHFFFAOYSA-N 0.000 claims description 2
• DHQVLDICLCUSQK-UHFFFAOYSA-N 5-[[(5-ethyl-2-phenylpiperidin-3-yl)amino]methyl]-6-methoxy-3-methyl-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one Chemical compound C=1C=2N(C)C(=O)C3CC3C=2C=C(OC)C=1CNC1CC(CC)CNC1C1=CC=CC=C1 DHQVLDICLCUSQK-UHFFFAOYSA-N 0.000 claims description 2
• SOCSKHWQEICIPM-UHFFFAOYSA-N 5-[[(5-ethyl-2-phenylpiperidin-3-yl)amino]methyl]-6-methoxy-3-methyl-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one;hydrochloride Chemical compound Cl.C=1C=2N(C)C(=O)C3CC3C=2C=C(OC)C=1CNC1CC(CC)CNC1C1=CC=CC=C1 SOCSKHWQEICIPM-UHFFFAOYSA-N 0.000 claims description 2
• BNTAFVLGVQQCBH-UHFFFAOYSA-N 5-[[(6-ethyl-2-phenylpiperidin-3-yl)amino]methyl]-6-methoxy-3,3-dimethyl-1h-inden-2-one Chemical compound N1C(CC)CCC(NCC=2C(=CC3=C(C(C(=O)C3)(C)C)C=2)OC)C1C1=CC=CC=C1 BNTAFVLGVQQCBH-UHFFFAOYSA-N 0.000 claims description 2
• KDGDTPNBDMVKHC-UHFFFAOYSA-N 5-[[(6-ethyl-2-phenylpiperidin-3-yl)amino]methyl]-6-methoxy-3-methyl-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one Chemical compound N1C(CC)CCC(NCC=2C(=CC=3C4CC4C(=O)N(C)C=3C=2)OC)C1C1=CC=CC=C1 KDGDTPNBDMVKHC-UHFFFAOYSA-N 0.000 claims description 2
• CQBITSBAANLPMH-UHFFFAOYSA-N 5-[[(6-ethyl-2-phenylpiperidin-3-yl)amino]methyl]-6-methoxy-3-methyl-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one;hydrochloride Chemical compound Cl.N1C(CC)CCC(NCC=2C(=CC=3C4CC4C(=O)N(C)C=3C=2)OC)C1C1=CC=CC=C1 CQBITSBAANLPMH-UHFFFAOYSA-N 0.000 claims description 2
• IXYLCHJLGMBMJN-UHFFFAOYSA-N 5-ethyl-2-phenylpiperidin-3-amine Chemical compound NC1CC(CC)CNC1C1=CC=CC=C1 IXYLCHJLGMBMJN-UHFFFAOYSA-N 0.000 claims description 2
• DJWDAEWJZSVWOF-UHFFFAOYSA-N 5-methoxy-1,3,3-trimethyl-2-oxopyrrolo[3,2-b]pyridine-6-carbaldehyde Chemical compound C1=C(C=O)C(OC)=NC2=C1N(C)C(=O)C2(C)C DJWDAEWJZSVWOF-UHFFFAOYSA-N 0.000 claims description 2
• FYXJYIVKIOJESY-UHFFFAOYSA-N 5-methyl-2-phenylpiperidin-3-amine Chemical compound NC1CC(C)CNC1C1=CC=CC=C1 FYXJYIVKIOJESY-UHFFFAOYSA-N 0.000 claims description 2
• QRHWCKUVIQEDQS-UHFFFAOYSA-N 6,6-dimethyl-2-phenylpiperidin-3-amine Chemical compound N1C(C)(C)CCC(N)C1C1=CC=CC=C1 QRHWCKUVIQEDQS-UHFFFAOYSA-N 0.000 claims description 2
• MQCQLCXCEBRCHC-UHFFFAOYSA-N 6-[[(2-phenylpiperidin-3-yl)amino]methyl]-2,3-dihydrochromen-4-one Chemical compound C1=C2C(=O)CCOC2=CC=C1CNC1CCCNC1C1=CC=CC=C1 MQCQLCXCEBRCHC-UHFFFAOYSA-N 0.000 claims description 2
• DHIGJOVSQHKPRR-UHFFFAOYSA-N 6-cyclopropyloxy-1-methyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound C1CCNC(C=2C=CC=CC=2)C1NCC=1C=C2N(C)C(=O)CCC2=CC=1OC1CC1 DHIGJOVSQHKPRR-UHFFFAOYSA-N 0.000 claims description 2
• NVXIUPMKRIMRRJ-UHFFFAOYSA-N 6-ethoxy-1,3,3-trimethyl-5-[[(2-phenylpiperidin-3-yl)amino]methyl]indol-2-one Chemical compound CCOC1=CC=2N(C)C(=O)C(C)(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 NVXIUPMKRIMRRJ-UHFFFAOYSA-N 0.000 claims description 2
• DFGDTVWWLZOWAP-UHFFFAOYSA-N 6-ethoxy-1-methyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound CCOC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 DFGDTVWWLZOWAP-UHFFFAOYSA-N 0.000 claims description 2
• YXOCELGJOBHHSV-UHFFFAOYSA-N 6-ethyl-2-phenylpiperidin-3-amine Chemical compound N1C(CC)CCC(N)C1C1=CC=CC=C1 YXOCELGJOBHHSV-UHFFFAOYSA-N 0.000 claims description 2
• LOZLQBRZGVCSJE-UHFFFAOYSA-N 6-hydroxy-1-methyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound C1=C2N(C)C(=O)CCC2=CC(O)=C1CNC1CCCNC1C1=CC=CC=C1 LOZLQBRZGVCSJE-UHFFFAOYSA-N 0.000 claims description 2
• GCCGJEDAGKCDGQ-UHFFFAOYSA-N 6-methoxy-1,3,3-trimethyl-5-[[(2-phenyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-yl)amino]methyl]indol-2-one Chemical compound COC1=CC=2N(C)C(=O)C(C)(C)C=2C=C1CNC1C2CCCC2NC1C1=CC=CC=C1 GCCGJEDAGKCDGQ-UHFFFAOYSA-N 0.000 claims description 2
• ZLSPKYQWTSFEDU-UHFFFAOYSA-N 6-methoxy-1,3,3-trimethyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-4h-quinolin-2-one Chemical compound COC1=CC=2CC(C)(C)C(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 ZLSPKYQWTSFEDU-UHFFFAOYSA-N 0.000 claims description 2
• YSHAEBZBAQRJFZ-UHFFFAOYSA-N 6-methoxy-1,3-dimethyl-5-[[(2-phenylpiperidin-3-yl)amino]methyl]-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one Chemical compound COC1=CC=2C3C(C)C3C(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 YSHAEBZBAQRJFZ-UHFFFAOYSA-N 0.000 claims description 2
• GWXXVYZVPGDRLK-UHFFFAOYSA-N 6-methoxy-1,3-dimethyl-5-[[(2-phenylpiperidin-3-yl)amino]methyl]-3h-indol-2-one Chemical compound COC1=CC=2N(C)C(=O)C(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 GWXXVYZVPGDRLK-UHFFFAOYSA-N 0.000 claims description 2
• CMVIJVKTWJCLLN-UHFFFAOYSA-N 6-methoxy-1,3-dimethyl-7-[[(1-methyl-2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CC(C)C(=O)N(C)C=2C=C1CNC1CCCN(C)C1C1=CC=CC=C1 CMVIJVKTWJCLLN-UHFFFAOYSA-N 0.000 claims description 2
• JGMRIUVVBFUCHE-UHFFFAOYSA-N 6-methoxy-1,3-dimethyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CC(C)C(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 JGMRIUVVBFUCHE-UHFFFAOYSA-N 0.000 claims description 2
• PLJQBWDFKVJBBQ-UHFFFAOYSA-N 6-methoxy-1,4-dimethyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2C(C)CC(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 PLJQBWDFKVJBBQ-UHFFFAOYSA-N 0.000 claims description 2
• ZLRLISQUXIBXRQ-UHFFFAOYSA-N 6-methoxy-1-methyl-3-(10-phenyl-1,9-diazaspiro[4.5]decan-3-yl)-3,4-dihydroquinolin-2-one Chemical compound C1C2=CC(OC)=CC=C2N(C)C(=O)C1C(C1)CNC21CCCNC2C1=CC=CC=C1 ZLRLISQUXIBXRQ-UHFFFAOYSA-N 0.000 claims description 2
• HULWXPLJZSSABB-UHFFFAOYSA-N 6-methoxy-1-methyl-5-[[(2-phenylpiperidin-3-yl)amino]methyl]-3h-indol-2-one Chemical compound COC1=CC=2N(C)C(=O)CC=2C=C1CNC1CCCNC1C1=CC=CC=C1 HULWXPLJZSSABB-UHFFFAOYSA-N 0.000 claims description 2
• OFEQZGBQBJFODT-UHFFFAOYSA-N 6-methoxy-1-methyl-7-(10-phenyl-1-oxa-9-azaspiro[4.5]decan-3-yl)-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1C(C1)COC21CCCNC2C1=CC=CC=C1 OFEQZGBQBJFODT-UHFFFAOYSA-N 0.000 claims description 2
• BDPKRKPESNIYJW-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-phenyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1C2CCCC2NC1C1=CC=CC=C1 BDPKRKPESNIYJW-UHFFFAOYSA-N 0.000 claims description 2
• RVEJGANTWCKHQW-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-phenyl-1-propan-2-ylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCN(C(C)C)C1C1=CC=CC=C1 RVEJGANTWCKHQW-UHFFFAOYSA-N 0.000 claims description 2
• RTEXWLWWYFLKFZ-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-phenyl-6-propan-2-ylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCC(C(C)C)NC1C1=CC=CC=C1 RTEXWLWWYFLKFZ-UHFFFAOYSA-N 0.000 claims description 2
• LKGQQWSQYZASSN-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-phenyl-6-propylpiperidin-3-yl)amino]methyl]-3,4-dihydro-1,5-naphthyridin-2-one Chemical compound N1C(CCC)CCC(NCC=2C(=NC=3CCC(=O)N(C)C=3C=2)OC)C1C1=CC=CC=C1 LKGQQWSQYZASSN-UHFFFAOYSA-N 0.000 claims description 2
• DDCMUENKQBXXPI-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-phenyl-6-propylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one;hydrochloride Chemical compound Cl.N1C(CCC)CCC(NCC=2C(=CC=3CCC(=O)N(C)C=3C=2)OC)C1C1=CC=CC=C1 DDCMUENKQBXXPI-UHFFFAOYSA-N 0.000 claims description 2
• CGVFPUYVFBJOCY-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 CGVFPUYVFBJOCY-UHFFFAOYSA-N 0.000 claims description 2
• GEKWGAQENFNMEE-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(6-methyl-2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydro-1,5-naphthyridin-2-one Chemical compound COC1=NC=2CCC(=O)N(C)C=2C=C1CNC1CCC(C)NC1C1=CC=CC=C1 GEKWGAQENFNMEE-UHFFFAOYSA-N 0.000 claims description 2
• FEZABWCIXRPPNV-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(6-methyl-2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one;hydrochloride Chemical compound Cl.COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCC(C)NC1C1=CC=CC=C1 FEZABWCIXRPPNV-UHFFFAOYSA-N 0.000 claims description 2
• RTEXWLWWYFLKFZ-MCEYFSPLSA-N 6-methoxy-1-methyl-7-[[[(2s,3s,6s)-2-phenyl-6-propan-2-ylpiperidin-3-yl]amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound C1([C@@H]2N[C@@H](CC[C@@H]2NCC2=CC=3N(C)C(=O)CCC=3C=C2OC)C(C)C)=CC=CC=C1 RTEXWLWWYFLKFZ-MCEYFSPLSA-N 0.000 claims description 2
• DIFSOFHEVZHGIA-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[[1-[(5-methyl-1h-imidazol-4-yl)methyl]-2-phenylpiperidin-3-yl]amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC(C1C=2C=CC=CC=2)CCCN1CC=1NC=NC=1C DIFSOFHEVZHGIA-UHFFFAOYSA-N 0.000 claims description 2
• MJBBHDGFDSKPCQ-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[[1-[(5-oxo-1,2-dihydro-1,2,4-triazol-3-yl)methyl]-2-phenylpiperidin-3-yl]amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC(C1C=2C=CC=CC=2)CCCN1CC1=NC(=O)NN1 MJBBHDGFDSKPCQ-UHFFFAOYSA-N 0.000 claims description 2
• PEDFDVZVHJWUOI-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[[2-phenyl-1-(2-pyridin-2-ylacetyl)piperidin-3-yl]amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCN(C(=O)CC=2N=CC=CC=2)C1C1=CC=CC=C1 PEDFDVZVHJWUOI-UHFFFAOYSA-N 0.000 claims description 2
• HBMBWAYNFCJVCP-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[[2-phenyl-1-(2-pyridin-3-ylacetyl)piperidin-3-yl]amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCN(C(=O)CC=2C=NC=CC=2)C1C1=CC=CC=C1 HBMBWAYNFCJVCP-UHFFFAOYSA-N 0.000 claims description 2
• XGVCYWRBJRAUBE-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[[2-phenyl-1-(2-pyridin-4-ylacetyl)piperidin-3-yl]amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCN(C(=O)CC=2C=CN=CC=2)C1C1=CC=CC=C1 XGVCYWRBJRAUBE-UHFFFAOYSA-N 0.000 claims description 2
• OAFXWOJYFZDTGV-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[[6-(2-methylpropyl)-2-phenylpiperidin-3-yl]amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCC(CC(C)C)NC1C1=CC=CC=C1 OAFXWOJYFZDTGV-UHFFFAOYSA-N 0.000 claims description 2
• MMKKLEQWOWSEHN-UHFFFAOYSA-N 6-methoxy-1-methylsulfonyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(S(C)(=O)=O)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 MMKKLEQWOWSEHN-UHFFFAOYSA-N 0.000 claims description 2
• RSRCKKPTRRRDEO-UHFFFAOYSA-N 6-methoxy-2-methyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroisoquinolin-1-one Chemical compound COC1=CC=2CCN(C)C(=O)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 RSRCKKPTRRRDEO-UHFFFAOYSA-N 0.000 claims description 2
• CTTBPHLWLPQOGL-UHFFFAOYSA-N 6-methoxy-3-methyl-2-oxo-1a,7b-dihydro-1h-cyclopropa[c]quinoline-5-carbaldehyde Chemical compound C12CC2C(=O)N(C)C2=C1C=C(OC)C(C=O)=C2 CTTBPHLWLPQOGL-UHFFFAOYSA-N 0.000 claims description 2
• IQZJXFQRUACVOJ-UHFFFAOYSA-N 6-methoxy-3-methyl-5-[[(2-phenyl-5-propylpiperidin-3-yl)amino]methyl]-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one Chemical compound C=1C=2N(C)C(=O)C3CC3C=2C=C(OC)C=1CNC1CC(CCC)CNC1C1=CC=CC=C1 IQZJXFQRUACVOJ-UHFFFAOYSA-N 0.000 claims description 2
• FNXKJICMOJIHEN-UHFFFAOYSA-N 6-methoxy-3-methyl-5-[[(2-phenyl-5-propylpiperidin-3-yl)amino]methyl]-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one;hydrochloride Chemical compound Cl.C=1C=2N(C)C(=O)C3CC3C=2C=C(OC)C=1CNC1CC(CCC)CNC1C1=CC=CC=C1 FNXKJICMOJIHEN-UHFFFAOYSA-N 0.000 claims description 2
• ZUHPJRGUJLZNRH-UHFFFAOYSA-N 6-methoxy-3-methyl-5-[[(2-phenyl-6-propylpiperidin-3-yl)amino]methyl]-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one Chemical compound N1C(CCC)CCC(NCC=2C(=CC=3C4CC4C(=O)N(C)C=3C=2)OC)C1C1=CC=CC=C1 ZUHPJRGUJLZNRH-UHFFFAOYSA-N 0.000 claims description 2
• OYGOQIONVYFBBD-UHFFFAOYSA-N 6-methoxy-3-methyl-5-[[(2-phenyl-6-propylpiperidin-3-yl)amino]methyl]-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one;hydrochloride Chemical compound Cl.N1C(CCC)CCC(NCC=2C(=CC=3C4CC4C(=O)N(C)C=3C=2)OC)C1C1=CC=CC=C1 OYGOQIONVYFBBD-UHFFFAOYSA-N 0.000 claims description 2
• BKJXGENYXSTOIO-UHFFFAOYSA-N 6-methoxy-3-methyl-5-[[(2-phenylpiperidin-3-yl)amino]methyl]-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one Chemical compound COC1=CC=2C3CC3C(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 BKJXGENYXSTOIO-UHFFFAOYSA-N 0.000 claims description 2
• GLJCXQACGRWIDQ-UHFFFAOYSA-N 6-methoxy-3-methyl-5-[[(5-methyl-2-phenylpiperidin-3-yl)amino]methyl]-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one;hydrochloride Chemical compound Cl.COC1=CC=2C3CC3C(=O)N(C)C=2C=C1CNC1CC(C)CNC1C1=CC=CC=C1 GLJCXQACGRWIDQ-UHFFFAOYSA-N 0.000 claims description 2
• ZQLWJXWFUMAHGR-UHFFFAOYSA-N 6-methoxy-3-methyl-5-[[(6-methyl-2-phenylpiperidin-3-yl)amino]methyl]-1a,7b-dihydro-1h-cyclopropa[c]quinolin-2-one;hydrochloride Chemical compound Cl.COC1=CC=2C3CC3C(=O)N(C)C=2C=C1CNC1CCC(C)NC1C1=CC=CC=C1 ZQLWJXWFUMAHGR-UHFFFAOYSA-N 0.000 claims description 2
• FTHZLRJBWMZQMI-UHFFFAOYSA-N 6-methoxy-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydro-1h-quinolin-2-one Chemical compound COC1=CC=2CCC(=O)NC=2C=C1CNC1CCCNC1C1=CC=CC=C1 FTHZLRJBWMZQMI-UHFFFAOYSA-N 0.000 claims description 2
• QWQWNOSYGKUEHP-UHFFFAOYSA-N 6-methoxy-7-[[[1-(2-methoxyethyl)-2-phenylpiperidin-3-yl]amino]methyl]-1-methyl-3,4-dihydroquinolin-2-one Chemical compound COCCN1CCCC(NCC=2C(=CC=3CCC(=O)N(C)C=3C=2)OC)C1C1=CC=CC=C1 QWQWNOSYGKUEHP-UHFFFAOYSA-N 0.000 claims description 2
• RIRLOSAVSUPMQW-UHFFFAOYSA-N 6-methyl-2-phenylpiperidin-3-amine Chemical compound N1C(C)CCC(N)C1C1=CC=CC=C1 RIRLOSAVSUPMQW-UHFFFAOYSA-N 0.000 claims description 2
• HZODYFQVNDOPPP-UHFFFAOYSA-N 7-[[(6,6-dimethyl-2-phenylpiperidin-3-yl)amino]methyl]-6-methoxy-1-methyl-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCC(C)(C)NC1C1=CC=CC=C1 HZODYFQVNDOPPP-UHFFFAOYSA-N 0.000 claims description 2
• IYTRKIYNYOPXMT-UHFFFAOYSA-N 7-[[(6-ethyl-2-phenylpiperidin-3-yl)amino]methyl]-6-methoxy-1-methyl-3,4-dihydro-1,5-naphthyridin-2-one Chemical compound N1C(CC)CCC(NCC=2C(=NC=3CCC(=O)N(C)C=3C=2)OC)C1C1=CC=CC=C1 IYTRKIYNYOPXMT-UHFFFAOYSA-N 0.000 claims description 2
• OGURKKDDDYZTMV-UHFFFAOYSA-N 7-[[(6-ethyl-2-phenylpiperidin-3-yl)amino]methyl]-6-methoxy-1-methyl-3,4-dihydroquinolin-2-one;hydrochloride Chemical compound Cl.N1C(CC)CCC(NCC=2C(=CC=3CCC(=O)N(C)C=3C=2)OC)C1C1=CC=CC=C1 OGURKKDDDYZTMV-UHFFFAOYSA-N 0.000 claims description 2
• BMXSFXWRNPMCDK-UHFFFAOYSA-N 7-[[(6-tert-butyl-2-phenylpiperidin-3-yl)amino]methyl]-6-methoxy-1-methyl-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCC(C(C)(C)C)NC1C1=CC=CC=C1 BMXSFXWRNPMCDK-UHFFFAOYSA-N 0.000 claims description 2
• REPALKDEXGYUKH-UHFFFAOYSA-N 7-[[[1-(1h-imidazol-5-ylmethyl)-2-phenylpiperidin-3-yl]amino]methyl]-6-methoxy-1-methyl-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC(C1C=2C=CC=CC=2)CCCN1CC1=CNC=N1 REPALKDEXGYUKH-UHFFFAOYSA-N 0.000 claims description 2
• YVQKSWKYWSFXEZ-UHFFFAOYSA-N 7-[[[1-(2-imidazol-1-ylacetyl)-2-phenylpiperidin-3-yl]amino]methyl]-6-methoxy-1-methyl-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCN(C(=O)CN2C=NC=C2)C1C1=CC=CC=C1 YVQKSWKYWSFXEZ-UHFFFAOYSA-N 0.000 claims description 2
• QGWXCCHMJRAMFI-UHFFFAOYSA-N 7-[[[1-[2-(dimethylamino)ethyl]-2-phenylpiperidin-3-yl]amino]methyl]-6-methoxy-1-methyl-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCN(CCN(C)C)C1C1=CC=CC=C1 QGWXCCHMJRAMFI-UHFFFAOYSA-N 0.000 claims description 2
• CWQOQQMXYSRVJV-UHFFFAOYSA-N 7-[[[2-(4-fluorophenyl)piperidin-3-yl]amino]methyl]-6-methoxy-1-methyl-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=C(F)C=C1 CWQOQQMXYSRVJV-UHFFFAOYSA-N 0.000 claims description 2
• MZDRKWFCBRXBIN-UHFFFAOYSA-N 7-[[[2-(4-fluorophenyl)piperidin-3-yl]amino]methyl]-6-methoxy-3,4-dihydro-1h-quinolin-2-one Chemical compound COC1=CC=2CCC(=O)NC=2C=C1CNC1CCCNC1C1=CC=C(F)C=C1 MZDRKWFCBRXBIN-UHFFFAOYSA-N 0.000 claims description 2
• IWBQQUAJJUFLFC-UHFFFAOYSA-N 8-fluoro-6-methoxy-1,4,4-trimethyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3h-quinolin-2-one Chemical compound COC1=CC(C(CC(=O)N2C)(C)C)=C2C(F)=C1CNC1CCCNC1C1=CC=CC=C1 IWBQQUAJJUFLFC-UHFFFAOYSA-N 0.000 claims description 2
• IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims description 2
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
• QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 claims description 2
• 125000002541 furyl group Chemical group 0.000 claims description 2
• 125000002883 imidazolyl group Chemical group 0.000 claims description 2
• 125000001041 indolyl group Chemical group 0.000 claims description 2
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
• 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
• 125000005322 morpholin-1-yl group Chemical group 0.000 claims description 2
• JJKOBNGZYPLKNG-UHFFFAOYSA-N n-(1-benzofuran-2-ylmethyl)-2-phenylpiperidin-3-amine Chemical compound C=1C2=CC=CC=C2OC=1CNC1CCCNC1C1=CC=CC=C1 JJKOBNGZYPLKNG-UHFFFAOYSA-N 0.000 claims description 2
• NJWCFWMYIRNQFK-UHFFFAOYSA-N n-(3h-benzimidazol-5-ylmethyl)-2-phenylpiperidin-3-amine Chemical compound C=1C=C2NC=NC2=CC=1CNC1CCCNC1C1=CC=CC=C1 NJWCFWMYIRNQFK-UHFFFAOYSA-N 0.000 claims description 2
• PPTYBUNVHZKQDO-UHFFFAOYSA-N n-(dibenzofuran-2-ylmethyl)-2-phenylpiperidin-3-amine Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1CNC1CCCNC1C1=CC=CC=C1 PPTYBUNVHZKQDO-UHFFFAOYSA-N 0.000 claims description 2
• CMEZNLVMECOKOE-UHFFFAOYSA-N n-(furan-2-ylmethyl)-2-phenylpiperidin-3-amine Chemical compound C=1C=COC=1CNC1CCCNC1C1=CC=CC=C1 CMEZNLVMECOKOE-UHFFFAOYSA-N 0.000 claims description 2
• YUAALXIAYQHJPD-UHFFFAOYSA-N n-[(2,2-dimethyl-3,4-dihydrochromen-6-yl)methyl]-2-phenylpiperidin-3-amine Chemical compound C=1C=C2OC(C)(C)CCC2=CC=1CNC1CCCNC1C1=CC=CC=C1 YUAALXIAYQHJPD-UHFFFAOYSA-N 0.000 claims description 2
• KHKIQNZLZXKGGJ-UHFFFAOYSA-N n-[(3,5-dimethyl-1-phenylpyrazol-4-yl)methyl]-2-phenylpiperidin-3-amine Chemical compound CC1=NN(C=2C=CC=CC=2)C(C)=C1CNC1CCCNC1C1=CC=CC=C1 KHKIQNZLZXKGGJ-UHFFFAOYSA-N 0.000 claims description 2
• PSNCQTJWUFKHMH-UHFFFAOYSA-N n-[(3-methyl-1-benzothiophen-2-yl)methyl]-2-phenylpiperidin-3-amine Chemical compound S1C2=CC=CC=C2C(C)=C1CNC1CCCNC1C1=CC=CC=C1 PSNCQTJWUFKHMH-UHFFFAOYSA-N 0.000 claims description 2
• ZGHKDLTYAGAMCA-UHFFFAOYSA-N n-[(3-methylthiophen-2-yl)methyl]-2-phenylpiperidin-3-amine Chemical compound C1=CSC(CNC2C(NCCC2)C=2C=CC=CC=2)=C1C ZGHKDLTYAGAMCA-UHFFFAOYSA-N 0.000 claims description 2
• DTLJAFHKDNQZQC-UHFFFAOYSA-N n-[(3-phenoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound C=1C=CC(OC=2C=CC=CC=2)=CC=1CNC1CCCNC1C1=CC=CC=C1 DTLJAFHKDNQZQC-UHFFFAOYSA-N 0.000 claims description 2
• NYXURIKZGFQVEF-UHFFFAOYSA-N n-[(4-phenoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1CNC1CCCNC1C1=CC=CC=C1 NYXURIKZGFQVEF-UHFFFAOYSA-N 0.000 claims description 2
• MQQRZHNDOQRTDI-UHFFFAOYSA-N n-[(5,7-dimethoxy-1h-indol-4-yl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC(OC)=C2NC=CC2=C1CNC1CCCNC1C1=CC=CC=C1 MQQRZHNDOQRTDI-UHFFFAOYSA-N 0.000 claims description 2
• XDHQBVNQIBXWJN-UHFFFAOYSA-N n-[(5-chloro-2-ethoxypyridin-3-yl)methyl]-2-phenylpiperidin-3-amine Chemical compound CCOC1=NC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NCCC1 XDHQBVNQIBXWJN-UHFFFAOYSA-N 0.000 claims description 2
• GNAIBYHTJMCWHH-UHFFFAOYSA-N n-[(5-chloro-2-methoxyphenyl)methyl]-2-phenyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-amine Chemical compound COC1=CC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NC2CCCC21 GNAIBYHTJMCWHH-UHFFFAOYSA-N 0.000 claims description 2
• CKHXZWXRRLRHIT-UHFFFAOYSA-N n-[(5-chloro-2-methoxypyridin-3-yl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=NC=C(Cl)C=C1CNC1C(C=2C=CC=CC=2)NCCC1 CKHXZWXRRLRHIT-UHFFFAOYSA-N 0.000 claims description 2
• SPMDJZYTWHJMID-UHFFFAOYSA-N n-[(5-chloro-3-methyl-1-phenylpyrazol-4-yl)methyl]-2-phenylpiperidin-3-amine Chemical compound CC1=NN(C=2C=CC=CC=2)C(Cl)=C1CNC1CCCNC1C1=CC=CC=C1 SPMDJZYTWHJMID-UHFFFAOYSA-N 0.000 claims description 2
• NWUOOEOHUYRMSR-UHFFFAOYSA-N n-[(5-ethylfuran-2-yl)methyl]-2-phenylpiperidin-3-amine Chemical compound O1C(CC)=CC=C1CNC1C(C=2C=CC=CC=2)NCCC1 NWUOOEOHUYRMSR-UHFFFAOYSA-N 0.000 claims description 2
• JPCQXVAHDFZJSJ-UHFFFAOYSA-N n-[(5-methoxy-1h-indol-3-yl)methyl]-2-phenylpiperidin-3-amine Chemical compound C12=CC(OC)=CC=C2NC=C1CNC1CCCNC1C1=CC=CC=C1 JPCQXVAHDFZJSJ-UHFFFAOYSA-N 0.000 claims description 2
• MUSHLONORAVGQQ-UHFFFAOYSA-N n-[(5-methyl-1-benzothiophen-3-yl)methyl]-2-phenylpiperidin-3-amine Chemical compound C12=CC(C)=CC=C2SC=C1CNC1CCCNC1C1=CC=CC=C1 MUSHLONORAVGQQ-UHFFFAOYSA-N 0.000 claims description 2
• SJMCKNCLJPVKGW-UHFFFAOYSA-N n-[(5-methylfuran-2-yl)methyl]-2-phenylpiperidin-3-amine Chemical compound O1C(C)=CC=C1CNC1C(C=2C=CC=CC=2)NCCC1 SJMCKNCLJPVKGW-UHFFFAOYSA-N 0.000 claims description 2
• UOUIGQQNUPRGRM-UHFFFAOYSA-N n-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-1-(1,2,4-oxadiazol-3-ylmethyl)-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)N(CC2=NOC=N2)CCC1 UOUIGQQNUPRGRM-UHFFFAOYSA-N 0.000 claims description 2
• VBNJYKLYPOEOKG-UHFFFAOYSA-N n-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-1-(2-pyrrolidin-1-ylethyl)piperidin-3-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)N(CCN2CCCC2)CCC1 VBNJYKLYPOEOKG-UHFFFAOYSA-N 0.000 claims description 2
• HNSXKUTWCZYNTB-UHFFFAOYSA-N n-[[3-chloro-2-(4-fluorophenoxy)pyridin-4-yl]methyl]-2-phenylpiperidin-3-amine Chemical compound C1=CC(F)=CC=C1OC1=NC=CC(CNC2C(NCCC2)C=2C=CC=CC=2)=C1Cl HNSXKUTWCZYNTB-UHFFFAOYSA-N 0.000 claims description 2
• 125000005493 quinolyl group Chemical group 0.000 claims description 2
• 210000002784 stomach Anatomy 0.000 claims description 2
• 125000001544 thienyl group Chemical group 0.000 claims description 2
• 125000001425 triazolyl group Chemical group 0.000 claims description 2
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 4
• KZQLNPQPMUYPSP-UHFFFAOYSA-N 6-ethoxy-1,3,3-trimethyl-5-[[(2-phenyl-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-3-yl)amino]methyl]indol-2-one Chemical compound CCOC1=CC=2N(C)C(=O)C(C)(C)C=2C=C1CNC1C2CCCC2NC1C1=CC=CC=C1 KZQLNPQPMUYPSP-UHFFFAOYSA-N 0.000 claims 2
• 101100073357 Streptomyces halstedii sch2 gene Proteins 0.000 claims 2
• 210000001198 duodenum Anatomy 0.000 claims 2
• XAHYMEDFEVWJKE-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-phenyl-1-propylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound CCCN1CCCC(NCC=2C(=CC=3CCC(=O)N(C)C=3C=2)OC)C1C1=CC=CC=C1 XAHYMEDFEVWJKE-UHFFFAOYSA-N 0.000 claims 1
• BUQFPAQPCPHWSD-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[[1-(1,2,4-oxadiazol-3-ylmethyl)-2-phenylpiperidin-3-yl]amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC(C1C=2C=CC=CC=2)CCCN1CC=1N=CON=1 BUQFPAQPCPHWSD-UHFFFAOYSA-N 0.000 claims 1
• HVMVUMXJXSKWHJ-UHFFFAOYSA-N 7-[[[1-(2,3-dihydroxypropyl)-2-phenylpiperidin-3-yl]amino]methyl]-6-methoxy-1-methyl-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCN(CC(O)CO)C1C1=CC=CC=C1 HVMVUMXJXSKWHJ-UHFFFAOYSA-N 0.000 claims 1
• ZJYBSHYFCNNBKT-UHFFFAOYSA-N n-[(5-methyl-3-phenyl-1,2-oxazol-4-yl)methyl]-2-phenylpiperidin-3-amine Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1CNC1CCCNC1C1=CC=CC=C1 ZJYBSHYFCNNBKT-UHFFFAOYSA-N 0.000 claims 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 138
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 122
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 102
• 238000006243 chemical reaction Methods 0.000 description 80
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 78
• 239000002904 solvent Substances 0.000 description 78
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 74
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 72
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 61
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 51
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
• 239000002585 base Substances 0.000 description 44
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 42
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
• 229910001868 water Inorganic materials 0.000 description 38
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 36
• 238000010992 reflux Methods 0.000 description 36
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 35
• 230000009467 reduction Effects 0.000 description 34
• 238000006722 reduction reaction Methods 0.000 description 34
• 239000012442 inert solvent Substances 0.000 description 25
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
• 239000002253 acid Substances 0.000 description 24
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 23
• 239000003054 catalyst Substances 0.000 description 21
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
• 150000001299 aldehydes Chemical class 0.000 description 19
• 230000002265 prevention Effects 0.000 description 19
• 230000002829 reductive effect Effects 0.000 description 19
• 239000011734 sodium Substances 0.000 description 19
• 208000008589 Obesity Diseases 0.000 description 18
• 235000020824 obesity Nutrition 0.000 description 18
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 17
• 239000002830 appetite depressant Substances 0.000 description 17
• GRTGGSXWHGKRSB-UHFFFAOYSA-N dichloromethyl methyl ether Chemical compound COC(Cl)Cl GRTGGSXWHGKRSB-UHFFFAOYSA-N 0.000 description 17
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 17
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
• VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 16
• 229940093499 ethyl acetate Drugs 0.000 description 16
• 235000019439 ethyl acetate Nutrition 0.000 description 16
• 238000002360 preparation method Methods 0.000 description 16
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 15
• 150000002466 imines Chemical class 0.000 description 15
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 14
• 239000003795 chemical substances by application Substances 0.000 description 14
• 239000000543 intermediate Substances 0.000 description 14
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 14
• 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 14
• 239000000243 solution Substances 0.000 description 14
• 239000011701 zinc Substances 0.000 description 14
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 13
• 229910000564 Raney nickel Inorganic materials 0.000 description 13
• VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 13
• NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 13
• 229910000104 sodium hydride Inorganic materials 0.000 description 13
• 229910052725 zinc Inorganic materials 0.000 description 13
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 12
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 12
• 239000007868 Raney catalyst Substances 0.000 description 12
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 12
• 239000000047 product Substances 0.000 description 12
• 229910052708 sodium Inorganic materials 0.000 description 12
• PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 12
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 11
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
• 230000001476 alcoholic effect Effects 0.000 description 11
• 239000003638 chemical reducing agent Substances 0.000 description 11
• 229910052744 lithium Inorganic materials 0.000 description 11
• 229960001078 lithium Drugs 0.000 description 11
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 10
• 238000007792 addition Methods 0.000 description 10
• 239000007864 aqueous solution Substances 0.000 description 10
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 10
• 230000022244 formylation Effects 0.000 description 10
• 238000006170 formylation reaction Methods 0.000 description 10
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 10
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• 239000003960 organic solvent Substances 0.000 description 9
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 9
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 8
• 239000005695 Ammonium acetate Substances 0.000 description 8
• KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 8
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 8
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
• 235000019257 ammonium acetate Nutrition 0.000 description 8
• 229940043376 ammonium acetate Drugs 0.000 description 8
• 229910052500 inorganic mineral Inorganic materials 0.000 description 8
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 8
• 235000010755 mineral Nutrition 0.000 description 8
• 239000011707 mineral Substances 0.000 description 8
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
• 150000002923 oximes Chemical class 0.000 description 8
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
• 229910000027 potassium carbonate Inorganic materials 0.000 description 8
• 229910000105 potassium hydride Inorganic materials 0.000 description 8
• 238000006268 reductive amination reaction Methods 0.000 description 8
• 229910000029 sodium carbonate Inorganic materials 0.000 description 8
• AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 8
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 7
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 7
• 239000000935 antidepressant agent Substances 0.000 description 7
• 229940005513 antidepressants Drugs 0.000 description 7
• UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 7
• 125000005843 halogen group Chemical group 0.000 description 7
• 238000007327 hydrogenolysis reaction Methods 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 235000017557 sodium bicarbonate Nutrition 0.000 description 7
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
• XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 7
• VOITXYVAKOUIBA-UHFFFAOYSA-N triethylaluminium Chemical compound CC[Al](CC)CC VOITXYVAKOUIBA-UHFFFAOYSA-N 0.000 description 7
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 6
• 208000019695 Migraine disease Diseases 0.000 description 6
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 6
• 235000019270 ammonium chloride Nutrition 0.000 description 6
• 239000000460 chlorine Substances 0.000 description 6
• HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 6
• 239000012467 final product Substances 0.000 description 6
• 150000004678 hydrides Chemical class 0.000 description 6
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 6
• 208000021722 neuropathic pain Diseases 0.000 description 6
• MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 6
• 229910003446 platinum oxide Inorganic materials 0.000 description 6
• 239000011591 potassium Substances 0.000 description 6
• 235000011181 potassium carbonates Nutrition 0.000 description 6
• NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 6
• 230000008569 process Effects 0.000 description 6
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 6
• 239000007858 starting material Substances 0.000 description 6
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
• QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 5
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
• 239000002841 Lewis acid Substances 0.000 description 5
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
• 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 5
• 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 5
• 101800003906 Substance P Proteins 0.000 description 5
• 102400000096 Substance P Human genes 0.000 description 5
• 229910021626 Tin(II) chloride Inorganic materials 0.000 description 5
• 150000001241 acetals Chemical class 0.000 description 5
• 230000002378 acidificating effect Effects 0.000 description 5
• 125000002252 acyl group Chemical group 0.000 description 5
• 210000000577 adipose tissue Anatomy 0.000 description 5
• 229940100198 alkylating agent Drugs 0.000 description 5
• 239000002168 alkylating agent Substances 0.000 description 5
• 239000005557 antagonist Substances 0.000 description 5
• 150000007514 bases Chemical class 0.000 description 5
• 230000003197 catalytic effect Effects 0.000 description 5
• 229910052801 chlorine Inorganic materials 0.000 description 5
• 239000012039 electrophile Substances 0.000 description 5
• 238000005984 hydrogenation reaction Methods 0.000 description 5
• 150000007517 lewis acids Chemical class 0.000 description 5
• 239000012280 lithium aluminium hydride Substances 0.000 description 5
• 229910052751 metal Inorganic materials 0.000 description 5
• 239000002184 metal Substances 0.000 description 5
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
• 239000002808 molecular sieve Substances 0.000 description 5
• 239000002899 monoamine oxidase inhibitor Substances 0.000 description 5
• 150000007524 organic acids Chemical class 0.000 description 5
• QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
• 239000011541 reaction mixture Substances 0.000 description 5
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 5
• 239000012312 sodium hydride Substances 0.000 description 5
• 235000011150 stannous chloride Nutrition 0.000 description 5
• 229910052718 tin Inorganic materials 0.000 description 5
• DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 4
• DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 4
• WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 4
• 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 4
• 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 4
• 229910000497 Amalgam Inorganic materials 0.000 description 4
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
• 206010006550 Bulimia nervosa Diseases 0.000 description 4
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
• 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 4
• 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 4
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 4
• QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
• 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 4
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• 102100037346 Substance-P receptor Human genes 0.000 description 4
• 102000003141 Tachykinin Human genes 0.000 description 4
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
• 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• 150000003934 aromatic aldehydes Chemical class 0.000 description 4
• 125000003118 aryl group Chemical group 0.000 description 4
• PPTSBERGOGHCHC-UHFFFAOYSA-N boron lithium Chemical compound [Li].[B] PPTSBERGOGHCHC-UHFFFAOYSA-N 0.000 description 4
• WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
• 229940124630 bronchodilator Drugs 0.000 description 4
• 201000011510 cancer Diseases 0.000 description 4
• 238000009903 catalytic hydrogenation reaction Methods 0.000 description 4
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
• 229960004316 cisplatin Drugs 0.000 description 4
• 238000009833 condensation Methods 0.000 description 4
• 230000005494 condensation Effects 0.000 description 4
• 229960004597 dexfenfluramine Drugs 0.000 description 4
• YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 4
• VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 4
• DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 4
• 201000006549 dyspepsia Diseases 0.000 description 4
• 230000000694 effects Effects 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 229960001582 fenfluramine Drugs 0.000 description 4
• KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
• VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
• 238000011065 in-situ storage Methods 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 150000002576 ketones Chemical class 0.000 description 4
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 4
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
• UBSPKGKFFQKZJB-UHFFFAOYSA-N methyl 4-nitrobutanoate Chemical compound COC(=O)CCC[N+]([O-])=O UBSPKGKFFQKZJB-UHFFFAOYSA-N 0.000 description 4
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
• 229910017604 nitric acid Inorganic materials 0.000 description 4
• 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 4
• 230000003287 optical effect Effects 0.000 description 4
• JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical class [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 4
• DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 4
• DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 4
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
• 238000010791 quenching Methods 0.000 description 4
• 230000000171 quenching effect Effects 0.000 description 4
• 230000005855 radiation Effects 0.000 description 4
• 229940044551 receptor antagonist Drugs 0.000 description 4
• 239000002464 receptor antagonist Substances 0.000 description 4
• 238000007363 ring formation reaction Methods 0.000 description 4
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
• WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 4
• 235000017550 sodium carbonate Nutrition 0.000 description 4
• 239000011877 solvent mixture Substances 0.000 description 4
• 108060008037 tachykinin Proteins 0.000 description 4
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
• HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 4
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
• JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 4
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
• TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 3
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
• PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 3
• SHPQVJNNBXMZRW-UHFFFAOYSA-N 6-butyldec-5-en-5-yltin Chemical compound CCCCC([Sn])=C(CCCC)CCCC SHPQVJNNBXMZRW-UHFFFAOYSA-N 0.000 description 3
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
• ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical compound CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 description 3
• 208000010235 Food Addiction Diseases 0.000 description 3
• 238000006842 Henry reaction Methods 0.000 description 3
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
• 239000012448 Lithium borohydride Substances 0.000 description 3
• 206010036049 Polycystic ovaries Diseases 0.000 description 3
• JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Inorganic materials [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 125000003545 alkoxy group Chemical group 0.000 description 3
• 229940025084 amphetamine Drugs 0.000 description 3
• 230000001430 anti-depressive effect Effects 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
• 229910000085 borane Inorganic materials 0.000 description 3
• MOOAHMCRPCTRLV-UHFFFAOYSA-N boron sodium Chemical compound [B].[Na] MOOAHMCRPCTRLV-UHFFFAOYSA-N 0.000 description 3
• 244000309464 bull Species 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 229950007046 chlorphentermine Drugs 0.000 description 3
• TZWKUQDQKPYNLL-UHFFFAOYSA-N cloforex Chemical compound CCOC(=O)NC(C)(C)CC1=CC=C(Cl)C=C1 TZWKUQDQKPYNLL-UHFFFAOYSA-N 0.000 description 3
• 229950008294 cloforex Drugs 0.000 description 3
• 229940127089 cytotoxic agent Drugs 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• CDHICTNQMQYRSM-UHFFFAOYSA-N di(propan-2-yl)alumane Chemical compound CC(C)[AlH]C(C)C CDHICTNQMQYRSM-UHFFFAOYSA-N 0.000 description 3
• UJTPZISIAWDGFF-UHFFFAOYSA-N ethenylsulfonylbenzene Chemical compound C=CS(=O)(=O)C1=CC=CC=C1 UJTPZISIAWDGFF-UHFFFAOYSA-N 0.000 description 3
• IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 3
• GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 239000003456 ion exchange resin Substances 0.000 description 3
• 229920003303 ion-exchange polymer Polymers 0.000 description 3
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
• 235000019341 magnesium sulphate Nutrition 0.000 description 3
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
• 229960001252 methamphetamine Drugs 0.000 description 3
• 210000005036 nerve Anatomy 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 3
• 239000000014 opioid analgesic Substances 0.000 description 3
• 235000005985 organic acids Nutrition 0.000 description 3
• 238000004806 packaging method and process Methods 0.000 description 3
• 229910052763 palladium Inorganic materials 0.000 description 3
• 239000004031 partial agonist Substances 0.000 description 3
• PZJBWSQQDMRZHY-UHFFFAOYSA-N picilorex Chemical compound CC1NC(C2CC2)CC1C1=CC=C(Cl)C=C1 PZJBWSQQDMRZHY-UHFFFAOYSA-N 0.000 description 3
• 229950003624 picilorex Drugs 0.000 description 3
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 3
• 235000015497 potassium bicarbonate Nutrition 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 125000006239 protecting group Chemical group 0.000 description 3
• UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 3
• 229960004425 sibutramine Drugs 0.000 description 3
• 239000012279 sodium borohydride Substances 0.000 description 3
• 229910000033 sodium borohydride Inorganic materials 0.000 description 3
• 229940001593 sodium carbonate Drugs 0.000 description 3
• 235000011121 sodium hydroxide Nutrition 0.000 description 3
• 239000001119 stannous chloride Substances 0.000 description 3
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 150000003512 tertiary amines Chemical class 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 239000011135 tin Substances 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 3
• 229920002554 vinyl polymer Polymers 0.000 description 3
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
• YAGBSNMZQKEFCO-SNVBAGLBSA-N (2r)-n-ethyl-1-phenylpropan-2-amine Chemical compound CCN[C@H](C)CC1=CC=CC=C1 YAGBSNMZQKEFCO-SNVBAGLBSA-N 0.000 description 2
• OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 description 2
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 2
• KWTSXDURSIMDCE-MRVPVSSYSA-N (R)-amphetamine Chemical compound C[C@@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-MRVPVSSYSA-N 0.000 description 2
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
• APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 2
• SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
• MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
• GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
• OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
• YKHQFTANTNMYPP-UHFFFAOYSA-N 2-bromopyridin-3-ol Chemical compound OC1=CC=CN=C1Br YKHQFTANTNMYPP-UHFFFAOYSA-N 0.000 description 2
• INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
• 208000032755 Anticipatory Vomiting Diseases 0.000 description 2
• 229910015900 BF3 Inorganic materials 0.000 description 2
• 208000032841 Bulimia Diseases 0.000 description 2
• KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
• 206010058019 Cancer Pain Diseases 0.000 description 2
• 239000004215 Carbon black (E152) Substances 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
• 208000037357 HIV infectious disease Diseases 0.000 description 2
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 229910010199 LiAl Inorganic materials 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 2
• 208000000112 Myalgia Diseases 0.000 description 2
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
• MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• 208000004550 Postoperative Pain Diseases 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 238000006859 Swern oxidation reaction Methods 0.000 description 2
• WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
• 208000012886 Vertigo Diseases 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 230000010933 acylation Effects 0.000 description 2
• 238000005917 acylation reaction Methods 0.000 description 2
• 125000003342 alkenyl group Chemical group 0.000 description 2
• 150000004703 alkoxides Chemical class 0.000 description 2
• AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
• 229910052782 aluminium Inorganic materials 0.000 description 2
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 150000008064 anhydrides Chemical class 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 230000000340 anti-metabolite Effects 0.000 description 2
• 239000002111 antiemetic agent Substances 0.000 description 2
• 229940100197 antimetabolite Drugs 0.000 description 2
• 239000002256 antimetabolite Substances 0.000 description 2
• YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 2
• 229960002837 benzphetamine Drugs 0.000 description 2
• HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
• 229960003237 betaine Drugs 0.000 description 2
• 230000027455 binding Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 229960003609 cathine Drugs 0.000 description 2
• 238000013375 chromatographic separation Methods 0.000 description 2
• LRXXRIXDSAEIOR-ZDUSSCGKSA-N clobenzorex Chemical compound C([C@H](C)NCC=1C(=CC=CC=1)Cl)C1=CC=CC=C1 LRXXRIXDSAEIOR-ZDUSSCGKSA-N 0.000 description 2
• 229960002492 clobenzorex Drugs 0.000 description 2
• HXCXASJHZQXCKK-UHFFFAOYSA-N clortermine Chemical compound CC(C)(N)CC1=CC=CC=C1Cl HXCXASJHZQXCKK-UHFFFAOYSA-N 0.000 description 2
• 229950000649 clortermine Drugs 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 229960003901 dacarbazine Drugs 0.000 description 2
• 238000010511 deprotection reaction Methods 0.000 description 2
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
• 229960003957 dexamethasone Drugs 0.000 description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
• 229960000632 dexamfetamine Drugs 0.000 description 2
• XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 2
• 229960004193 dextropropoxyphene Drugs 0.000 description 2
• 229960002069 diamorphine Drugs 0.000 description 2
• XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 2
• 229960004890 diethylpropion Drugs 0.000 description 2
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
• KZTYYGOKRVBIMI-UHFFFAOYSA-N diphenyl sulfone Chemical group C=1C=CC=CC=1S(=O)(=O)C1=CC=CC=C1 KZTYYGOKRVBIMI-UHFFFAOYSA-N 0.000 description 2
• AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 2
• 208000000718 duodenal ulcer Diseases 0.000 description 2
• 239000002895 emetic Substances 0.000 description 2
• 229960001003 etilamfetamine Drugs 0.000 description 2
• IQUFSXIQAFPIMR-UHFFFAOYSA-N fenproporex Chemical compound N#CCCNC(C)CC1=CC=CC=C1 IQUFSXIQAFPIMR-UHFFFAOYSA-N 0.000 description 2
• 229960005231 fenproporex Drugs 0.000 description 2
• IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
• 229960002464 fluoxetine Drugs 0.000 description 2
• 229960004038 fluvoxamine Drugs 0.000 description 2
• CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• 150000004675 formic acid derivatives Chemical class 0.000 description 2
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
• DLGIIZAHQPTVCJ-UHFFFAOYSA-N furfenorex Chemical compound C=1C=COC=1CN(C)C(C)CC1=CC=CC=C1 DLGIIZAHQPTVCJ-UHFFFAOYSA-N 0.000 description 2
• 229950005457 furfenorex Drugs 0.000 description 2
• 230000002140 halogenating effect Effects 0.000 description 2
• 230000026030 halogenation Effects 0.000 description 2
• 238000005658 halogenation reaction Methods 0.000 description 2
• 208000024798 heartburn Diseases 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
• 229930195733 hydrocarbon Natural products 0.000 description 2
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 150000002440 hydroxy compounds Chemical class 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 238000007917 intracranial administration Methods 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 239000003199 leukotriene receptor blocking agent Substances 0.000 description 2
• 229950005223 levamfetamine Drugs 0.000 description 2
• CETVQRFGPOGIQJ-UHFFFAOYSA-N lithium;hexane Chemical compound [Li+].CCCCC[CH2-] CETVQRFGPOGIQJ-UHFFFAOYSA-N 0.000 description 2
• NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
• 229960004961 mechlorethamine Drugs 0.000 description 2
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
• XXVROGAVTTXONC-UHFFFAOYSA-N mefenorex Chemical compound ClCCCNC(C)CC1=CC=CC=C1 XXVROGAVTTXONC-UHFFFAOYSA-N 0.000 description 2
• 229960001468 mefenorex Drugs 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 230000011278 mitosis Effects 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 229960005181 morphine Drugs 0.000 description 2
• YZLZPSJXMWGIFH-BCXQGASESA-N nalbuphine hydrochloride Chemical compound [H+].[Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 YZLZPSJXMWGIFH-BCXQGASESA-N 0.000 description 2
• 230000002981 neuropathic effect Effects 0.000 description 2
• 239000012454 non-polar solvent Substances 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 238000005949 ozonolysis reaction Methods 0.000 description 2
• 229960005489 paracetamol Drugs 0.000 description 2
• 229960002296 paroxetine Drugs 0.000 description 2
• UMWAUEZOGHNSCH-UHFFFAOYSA-N pentorex Chemical compound CC(N)(C)C(C)C1=CC=CC=C1 UMWAUEZOGHNSCH-UHFFFAOYSA-N 0.000 description 2
• 229950000821 pentorex Drugs 0.000 description 2
• 229960000436 phendimetrazine Drugs 0.000 description 2
• 229960003209 phenmetrazine Drugs 0.000 description 2
• 229960003562 phentermine Drugs 0.000 description 2
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
• 229960000395 phenylpropanolamine Drugs 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
• 239000002798 polar solvent Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
• IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
• 235000015320 potassium carbonate Nutrition 0.000 description 2
• 230000035935 pregnancy Effects 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• 239000000376 reactant Substances 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 230000008653 root damage Effects 0.000 description 2
• 150000003335 secondary amines Chemical class 0.000 description 2
• 230000020341 sensory perception of pain Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 229940076279 serotonin Drugs 0.000 description 2
• 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
• 229960002073 sertraline Drugs 0.000 description 2
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 235000015424 sodium Nutrition 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
• 235000011149 sulphuric acid Nutrition 0.000 description 2
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
• 208000004371 toothache Diseases 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
• ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
• VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 2
• 231100000889 vertigo Toxicity 0.000 description 2
• 238000006886 vinylation reaction Methods 0.000 description 2
• 239000011592 zinc chloride Substances 0.000 description 2
• VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 description 1
• YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
• FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
• DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
• PDVFSPNIEOYOQL-UHFFFAOYSA-N (4-methylphenyl)sulfonyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OS(=O)(=O)C1=CC=C(C)C=C1 PDVFSPNIEOYOQL-UHFFFAOYSA-N 0.000 description 1
• SVTKSKRNLMAUKF-HAIKCVHQSA-N (4r,4ar,7s,7ar,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O SVTKSKRNLMAUKF-HAIKCVHQSA-N 0.000 description 1
• ZGSZBVAEVPSPFM-HYTSPMEMSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC ZGSZBVAEVPSPFM-HYTSPMEMSA-N 0.000 description 1
• WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
• DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
• BCXHDORHMMZBBZ-DORFAMGDSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC BCXHDORHMMZBBZ-DORFAMGDSA-N 0.000 description 1
• MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
• KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
• TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
• YLPCXVWMHNNQGI-UHFFFAOYSA-N 1,2-diazabicyclo[3.2.1]octane Chemical compound C1C2CCN1NCC2 YLPCXVWMHNNQGI-UHFFFAOYSA-N 0.000 description 1
• VAOLKEBGHFLQAS-UHFFFAOYSA-N 1,3,3-trimethyl-5-[[(2-phenylpiperidin-3-yl)amino]methyl]-6-propan-2-yloxyindol-2-one Chemical compound CC(C)OC1=CC=2N(C)C(=O)C(C)(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 VAOLKEBGHFLQAS-UHFFFAOYSA-N 0.000 description 1
• YHELUCUIFBBFGG-UHFFFAOYSA-N 1,3-dibromo-5,5-diphenylimidazolidine-2,4-dione Chemical compound O=C1N(Br)C(=O)N(Br)C1(C=1C=CC=CC=1)C1=CC=CC=C1 YHELUCUIFBBFGG-UHFFFAOYSA-N 0.000 description 1
• WTAPZWXVSZMMDG-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 WTAPZWXVSZMMDG-UHFFFAOYSA-N 0.000 description 1
• CNGJXUSVJXWIIL-UHFFFAOYSA-N 1-bromo-1-iodoethane Chemical compound CC(Br)I CNGJXUSVJXWIIL-UHFFFAOYSA-N 0.000 description 1
• RYAGQMSEMGVLGY-UHFFFAOYSA-N 1-chloro-1-iodoethane Chemical compound CC(Cl)I RYAGQMSEMGVLGY-UHFFFAOYSA-N 0.000 description 1
• PPNCOQHHSGMKGI-UHFFFAOYSA-N 1-cyclononyldiazonane Chemical compound C1CCCCCCCC1N1NCCCCCCC1 PPNCOQHHSGMKGI-UHFFFAOYSA-N 0.000 description 1
• AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
• PFHGNIMWELIXGP-UHFFFAOYSA-N 1-nitropiperidine Chemical compound [O-][N+](=O)N1CCCCC1 PFHGNIMWELIXGP-UHFFFAOYSA-N 0.000 description 1
• CWMYWRMDANXCSB-UHFFFAOYSA-N 1-oxoethanesulfonic acid Chemical compound CC(=O)S(O)(=O)=O CWMYWRMDANXCSB-UHFFFAOYSA-N 0.000 description 1
• SOFQDLYSFOWTJX-UHFFFAOYSA-N 1-phenylpropan-2-amine;sulfuric acid Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1 SOFQDLYSFOWTJX-UHFFFAOYSA-N 0.000 description 1
• XQQZRZQVBFHBHL-UHFFFAOYSA-N 12-crown-4 Chemical compound C1COCCOCCOCCO1 XQQZRZQVBFHBHL-UHFFFAOYSA-N 0.000 description 1
• VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 1
• XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
• LZIPBJBQQPZLOR-UHFFFAOYSA-N 2-(4-methylphenyl)sulfonyloxyethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOS(=O)(=O)C1=CC=C(C)C=C1 LZIPBJBQQPZLOR-UHFFFAOYSA-N 0.000 description 1
• UCEXMJMSILZCHZ-UHFFFAOYSA-N 2-[(4-butoxybenzoyl)amino]acetic acid Chemical compound CCCCOC1=CC=C(C(=O)NCC(O)=O)C=C1 UCEXMJMSILZCHZ-UHFFFAOYSA-N 0.000 description 1
• MWGATWIBSKHFMR-UHFFFAOYSA-N 2-anilinoethanol Chemical compound OCCNC1=CC=CC=C1 MWGATWIBSKHFMR-UHFFFAOYSA-N 0.000 description 1
• BWJNSRABTDYPPK-UHFFFAOYSA-N 2-bromo-3-methoxy-5-nitropyridine Chemical compound COC1=CC([N+]([O-])=O)=CN=C1Br BWJNSRABTDYPPK-UHFFFAOYSA-N 0.000 description 1
• HJBGMPCMSWJZNH-UHFFFAOYSA-N 2-iodopyridin-3-ol Chemical compound OC1=CC=CN=C1I HJBGMPCMSWJZNH-UHFFFAOYSA-N 0.000 description 1
• WUPLOZFIOAEYMG-UHFFFAOYSA-N 2-methoxy-5-nitropyridine Chemical compound COC1=CC=C([N+]([O-])=O)C=N1 WUPLOZFIOAEYMG-UHFFFAOYSA-N 0.000 description 1
• HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
• LQIIEHBULBHJKX-UHFFFAOYSA-N 2-methylpropylalumane Chemical compound CC(C)C[AlH2] LQIIEHBULBHJKX-UHFFFAOYSA-N 0.000 description 1
• QSQFARNGNIZGAW-UHFFFAOYSA-N 2-methylsulfonyloxyethyl methanesulfonate Chemical compound CS(=O)(=O)OCCOS(C)(=O)=O QSQFARNGNIZGAW-UHFFFAOYSA-N 0.000 description 1
• DHXNGBMVPJHMBV-UHFFFAOYSA-N 3-(benzylazaniumyl)-3-methylbutanoate Chemical compound OC(=O)CC(C)(C)NCC1=CC=CC=C1 DHXNGBMVPJHMBV-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
• 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 description 1
• NBUHTTJGQKIBMR-UHFFFAOYSA-N 4,6-dimethylpyrimidin-5-amine Chemical compound CC1=NC=NC(C)=C1N NBUHTTJGQKIBMR-UHFFFAOYSA-N 0.000 description 1
• DYUTXEVRMPFGTH-UHFFFAOYSA-N 4-(2,5-dimethylphenyl)-5-methyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=C(C)C=2)C)=C1C DYUTXEVRMPFGTH-UHFFFAOYSA-N 0.000 description 1
• AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
• YZPKZHPNUYHYLE-UHFFFAOYSA-N 5-[[(6-ethyl-2-phenylpiperidin-3-yl)amino]methyl]-6-methoxy-1,3,3-trimethylindol-2-one Chemical compound N1C(CC)CCC(NCC=2C(=CC3=C(C(C(=O)N3C)(C)C)C=2)OC)C1C1=CC=CC=C1 YZPKZHPNUYHYLE-UHFFFAOYSA-N 0.000 description 1
• HHKFJMBCHRBJOW-UHFFFAOYSA-N 5-methoxy-1,3-dihydropyrrolo[3,2-b]pyridin-2-one Chemical compound COC1=CC=C2NC(=O)CC2=N1 HHKFJMBCHRBJOW-UHFFFAOYSA-N 0.000 description 1
• XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
• USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
• DSCOSIUAQUDGJM-UHFFFAOYSA-N 6-chloro-1h-pyrrolo[2,3-b]pyridine Chemical compound ClC1=CC=C2C=CNC2=N1 DSCOSIUAQUDGJM-UHFFFAOYSA-N 0.000 description 1
• MJFYSOWWQSGYKZ-UHFFFAOYSA-N 6-methoxy-1,4,4-trimethyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3h-quinolin-2-one Chemical compound COC1=CC(C(CC(=O)N2C)(C)C)=C2C=C1CNC1CCCNC1C1=CC=CC=C1 MJFYSOWWQSGYKZ-UHFFFAOYSA-N 0.000 description 1
• MYTGFJXLYDMGLE-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-pyridin-2-ylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=CC=N1 MYTGFJXLYDMGLE-UHFFFAOYSA-N 0.000 description 1
• AIRLQWXGHSUUCT-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-pyridin-3-ylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=CN=C1 AIRLQWXGHSUUCT-UHFFFAOYSA-N 0.000 description 1
• MPEQYSFKPXDCMB-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-pyridin-4-ylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=NC=C1 MPEQYSFKPXDCMB-UHFFFAOYSA-N 0.000 description 1
• REKPTZKEGCXNHL-UHFFFAOYSA-N 6-nitrohexan-3-one Chemical compound CCC(=O)CCC[N+]([O-])=O REKPTZKEGCXNHL-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• IKVWSROSKRBTMP-UHFFFAOYSA-N 8-benzyl-5-phenyl-8-azabicyclo[3.2.1]octan-4-amine Chemical compound NC1CCC2CCC1(C=1C=CC=CC=1)N2CC1=CC=CC=C1 IKVWSROSKRBTMP-UHFFFAOYSA-N 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 229910000761 Aluminium amalgam Inorganic materials 0.000 description 1
• 229910000567 Amalgam (chemistry) Inorganic materials 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 206010004716 Binge eating Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 208000010392 Bone Fractures Diseases 0.000 description 1
• 229940122155 Bradykinin receptor antagonist Drugs 0.000 description 1
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• MFSVVCUECPFTIW-UHFFFAOYSA-N C(=O)(OCC1=CC=CC=C1)C=1C(=C(C(=O)Cl)C=CC=1)Cl Chemical compound C(=O)(OCC1=CC=CC=C1)C=1C(=C(C(=O)Cl)C=CC=1)Cl MFSVVCUECPFTIW-UHFFFAOYSA-N 0.000 description 1
• GDEWSCZCZPVTEG-UHFFFAOYSA-N C=C[Mg]C=C Chemical compound C=C[Mg]C=C GDEWSCZCZPVTEG-UHFFFAOYSA-N 0.000 description 1
• YXLBXTMNJNCFRW-UHFFFAOYSA-N COC=1C=C2CC(C(N(C2=CC1)C)=O)C1CNC2(C1)CN(CCC2)C2=CC=CC=C2 Chemical compound COC=1C=C2CC(C(N(C2=CC1)C)=O)C1CNC2(C1)CN(CCC2)C2=CC=CC=C2 YXLBXTMNJNCFRW-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
• GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
• 208000006561 Cluster Headache Diseases 0.000 description 1
• FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
• 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
• 208000005171 Dysmenorrhea Diseases 0.000 description 1
• 206010013935 Dysmenorrhoea Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 206010015958 Eye pain Diseases 0.000 description 1
• 206010016059 Facial pain Diseases 0.000 description 1
• CXLOIJUDIPVKOU-UHFFFAOYSA-N Fludorex Chemical compound CNCC(OC)C1=CC=CC(C(F)(F)F)=C1 CXLOIJUDIPVKOU-UHFFFAOYSA-N 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 201000001498 Froelich syndrome Diseases 0.000 description 1
• 229940123431 GABA B receptor agonist Drugs 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
• 208000004454 Hyperalgesia Diseases 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 208000035154 Hyperesthesia Diseases 0.000 description 1
• 206010020710 Hyperphagia Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 208000027601 Inner ear disease Diseases 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 239000003810 Jones reagent Substances 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 208000007914 Labor Pain Diseases 0.000 description 1
• 208000035945 Labour pain Diseases 0.000 description 1
• JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
• 229910010220 LiAl4 Inorganic materials 0.000 description 1
• 208000008930 Low Back Pain Diseases 0.000 description 1
• ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
• 208000027530 Meniere disease Diseases 0.000 description 1
• XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
• 241000282341 Mustela putorius furo Species 0.000 description 1
• 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• 238000007126 N-alkylation reaction Methods 0.000 description 1
• AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 229920000557 Nafion® Polymers 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 238000006987 Nef reaction Methods 0.000 description 1
• 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 1
• 102000003797 Neuropeptides Human genes 0.000 description 1
• 108090000189 Neuropeptides Proteins 0.000 description 1
• 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
• 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
• 229940123925 Nicotinic receptor agonist Drugs 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
• UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
• BCGJBQBWUGVESK-KCTCKCTRSA-N Oxymorphone hydrochloride Chemical compound Cl.O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BCGJBQBWUGVESK-KCTCKCTRSA-N 0.000 description 1
• CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
• 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
• 208000004983 Phantom Limb Diseases 0.000 description 1
• 206010056238 Phantom pain Diseases 0.000 description 1
• RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
• 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
• MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• 206010066962 Procedural nausea Diseases 0.000 description 1
• 206010066963 Procedural vomiting Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 206010067171 Regurgitation Diseases 0.000 description 1
• 206010039424 Salivary hypersecretion Diseases 0.000 description 1
• 206010049002 Scar pain Diseases 0.000 description 1
• 208000008765 Sciatica Diseases 0.000 description 1
• 208000020221 Short stature Diseases 0.000 description 1
• 206010040744 Sinus headache Diseases 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 206010072005 Spinal pain Diseases 0.000 description 1
• 208000010040 Sprains and Strains Diseases 0.000 description 1
• 102100037342 Substance-K receptor Human genes 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 206010043269 Tension headache Diseases 0.000 description 1
• 208000008548 Tension-Type Headache Diseases 0.000 description 1
• 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 208000026928 Turner syndrome Diseases 0.000 description 1
• 208000001407 Vascular Headaches Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• GTIVDIGFCBZLEE-UHFFFAOYSA-M [Cl-].CC[Zn+] Chemical compound [Cl-].CC[Zn+] GTIVDIGFCBZLEE-UHFFFAOYSA-M 0.000 description 1
• JBHXQABAFSGYQJ-UHFFFAOYSA-M [Cl-].[Zn+]C=C Chemical compound [Cl-].[Zn+]C=C JBHXQABAFSGYQJ-UHFFFAOYSA-M 0.000 description 1
• FYJKEHKQUPSJDH-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;potassium Chemical compound [K].C[Si](C)(C)N[Si](C)(C)C FYJKEHKQUPSJDH-UHFFFAOYSA-N 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 1
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
• 239000012346 acetyl chloride Substances 0.000 description 1
• LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical compound CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 238000007171 acid catalysis Methods 0.000 description 1
• 239000003377 acid catalyst Substances 0.000 description 1
• 239000012445 acidic reagent Substances 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000009692 acute damage Effects 0.000 description 1
• 150000003855 acyl compounds Chemical class 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 229960001391 alfentanil Drugs 0.000 description 1
• 229960005380 alfentanil hydrochloride Drugs 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
• 229960004538 alprazolam Drugs 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 150000001413 amino acids Chemical group 0.000 description 1
• SYAKTDIEAPMBAL-UHFFFAOYSA-N aminorex Chemical compound O1C(N)=NCC1C1=CC=CC=C1 SYAKTDIEAPMBAL-UHFFFAOYSA-N 0.000 description 1
• 229950002544 aminorex Drugs 0.000 description 1
• 229960000836 amitriptyline Drugs 0.000 description 1
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 229960002519 amoxapine Drugs 0.000 description 1
• QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
• 238000002266 amputation Methods 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
• 150000001448 anilines Chemical class 0.000 description 1
• 230000000578 anorexic effect Effects 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000000454 anti-cipatory effect Effects 0.000 description 1
• 230000003474 anti-emetic effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 229940125684 antimigraine agent Drugs 0.000 description 1
• 239000002282 antimigraine agent Substances 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 239000003972 antineoplastic antibiotic Substances 0.000 description 1
• 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 1
• 239000000010 aprotic solvent Substances 0.000 description 1
• 239000011260 aqueous acid Substances 0.000 description 1
• 206010003074 arachnoiditis Diseases 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 229960000794 baclofen Drugs 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 238000005815 base catalysis Methods 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• MLWPJXZKQOPTKZ-UHFFFAOYSA-N benzenesulfonyl benzenesulfonate Chemical compound C=1C=CC=CC=1S(=O)(=O)OS(=O)(=O)C1=CC=CC=C1 MLWPJXZKQOPTKZ-UHFFFAOYSA-N 0.000 description 1
• CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
• PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
• KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
• 229940073608 benzyl chloride Drugs 0.000 description 1
• 150000003939 benzylamines Chemical class 0.000 description 1
• 229960002537 betamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
• 208000014679 binge eating disease Diseases 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
• 239000004327 boric acid Substances 0.000 description 1
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
• 210000003461 brachial plexus Anatomy 0.000 description 1
• 239000003152 bradykinin antagonist Substances 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 230000031709 bromination Effects 0.000 description 1
• 238000005893 bromination reaction Methods 0.000 description 1
• 229960004436 budesonide Drugs 0.000 description 1
• RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
• 229960001736 buprenorphine Drugs 0.000 description 1
• 229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
• UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
• 229960001058 bupropion Drugs 0.000 description 1
• QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
• 229960002495 buspirone Drugs 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
• 229960001113 butorphanol Drugs 0.000 description 1
• GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
• 229960001590 butorphanol tartrate Drugs 0.000 description 1
• 235000019577 caloric intake Nutrition 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
• 239000012829 chemotherapy agent Substances 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• 201000001883 cholelithiasis Diseases 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 208000013116 chronic cough Diseases 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• HAHOPPGVHWVBRR-UHFFFAOYSA-N clominorex Chemical compound O1C(N)=NCC1C1=CC=C(Cl)C=C1 HAHOPPGVHWVBRR-UHFFFAOYSA-N 0.000 description 1
• 229950000352 clominorex Drugs 0.000 description 1
• 229960004606 clomipramine Drugs 0.000 description 1
• DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
• 229960003120 clonazepam Drugs 0.000 description 1
• 229960004362 clorazepate Drugs 0.000 description 1
• XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
• 229960004415 codeine phosphate Drugs 0.000 description 1
• 229960003871 codeine sulfate Drugs 0.000 description 1
• UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 239000006184 cosolvent Substances 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 238000006356 dehydrogenation reaction Methods 0.000 description 1
• 229960003914 desipramine Drugs 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• YNLAOSYQHBDIKW-UHFFFAOYSA-M diethylaluminium chloride Chemical compound CC[Al](Cl)CC YNLAOSYQHBDIKW-UHFFFAOYSA-M 0.000 description 1
• HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
• 208000010643 digestive system disease Diseases 0.000 description 1
• RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
• 229960000920 dihydrocodeine Drugs 0.000 description 1
• 229960002705 dihydrocodeine bitartrate Drugs 0.000 description 1
• HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
• QDYBCIWLGJMJGO-UHFFFAOYSA-N dinitromethanone Chemical compound [O-][N+](=O)C(=O)[N+]([O-])=O QDYBCIWLGJMJGO-UHFFFAOYSA-N 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 1
• 229950004794 dizocilpine Drugs 0.000 description 1
• FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
• 229960001253 domperidone Drugs 0.000 description 1
• 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 229960005426 doxepin Drugs 0.000 description 1
• ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
• 230000035622 drinking Effects 0.000 description 1
• 235000005686 eating Nutrition 0.000 description 1
• 150000002081 enamines Chemical class 0.000 description 1
• 238000003821 enantio-separation Methods 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000006345 epimerization reaction Methods 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
• 229960004943 ergotamine Drugs 0.000 description 1
• XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
• 239000004210 ether based solvent Substances 0.000 description 1
• UUACHWPIESZRTJ-UHFFFAOYSA-N ethyl 2-bromoethaneperoxoate Chemical compound CCOOC(=O)CBr UUACHWPIESZRTJ-UHFFFAOYSA-N 0.000 description 1
• JDCIBQNRJNANBE-UHFFFAOYSA-N ethyl 4-nitrobutanoate Chemical compound CCOC(=O)CCC[N+]([O-])=O JDCIBQNRJNANBE-UHFFFAOYSA-N 0.000 description 1
• PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
• OZECFIJVSAYAPH-UHFFFAOYSA-N ethyl-di(propan-2-yl)azanium;chloride Chemical compound Cl.CCN(C(C)C)C(C)C OZECFIJVSAYAPH-UHFFFAOYSA-N 0.000 description 1
• UAIZDWNSWGTKFZ-UHFFFAOYSA-L ethylaluminum(2+);dichloride Chemical compound CC[Al](Cl)Cl UAIZDWNSWGTKFZ-UHFFFAOYSA-L 0.000 description 1
• BLHLJVCOVBYQQS-UHFFFAOYSA-N ethyllithium Chemical compound [Li]CC BLHLJVCOVBYQQS-UHFFFAOYSA-N 0.000 description 1
• AGUDKYVAXRDJLV-UHFFFAOYSA-N ethynyllithium Chemical compound [Li]C#C AGUDKYVAXRDJLV-UHFFFAOYSA-N 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• BAQKJENAVQLANS-UHFFFAOYSA-N fenbutrazate Chemical compound C=1C=CC=CC=1C(CC)C(=O)OCCN(C1C)CCOC1C1=CC=CC=C1 BAQKJENAVQLANS-UHFFFAOYSA-N 0.000 description 1
• 229960002533 fenbutrazate Drugs 0.000 description 1
• 229960002428 fentanyl Drugs 0.000 description 1
• 229960004207 fentanyl citrate Drugs 0.000 description 1
• 229950002723 fludorex Drugs 0.000 description 1
• NMGYDYBWRZHLHR-UHFFFAOYSA-N fluminorex Chemical compound O1C(N)=NCC1C1=CC=C(C(F)(F)F)C=C1 NMGYDYBWRZHLHR-UHFFFAOYSA-N 0.000 description 1
• 229950007852 fluminorex Drugs 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000004052 folic acid antagonist Substances 0.000 description 1
• 235000012631 food intake Nutrition 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229960000647 gepirone Drugs 0.000 description 1
• QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
• 229960003727 granisetron Drugs 0.000 description 1
• 229960002158 halazepam Drugs 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 150000002373 hemiacetals Chemical class 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• NEXSMEBSBIABKL-UHFFFAOYSA-N hexamethyldisilane Chemical compound C[Si](C)(C)[Si](C)(C)C NEXSMEBSBIABKL-UHFFFAOYSA-N 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
• 229960000240 hydrocodone Drugs 0.000 description 1
• 229960002764 hydrocodone bitartrate Drugs 0.000 description 1
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
• WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
• 229960001410 hydromorphone Drugs 0.000 description 1
• 229960002738 hydromorphone hydrochloride Drugs 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 229960004801 imipramine Drugs 0.000 description 1
• BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 208000021267 infertility disease Diseases 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 239000013067 intermediate product Substances 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 229950003599 ipsapirone Drugs 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 229960002672 isocarboxazid Drugs 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 150000004715 keto acids Chemical class 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
• RWTWIZDKEIWLKQ-IWWMGODWSA-N levorphan tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 RWTWIZDKEIWLKQ-IWWMGODWSA-N 0.000 description 1
• 229960003406 levorphanol Drugs 0.000 description 1
• 229960005157 levorphanol tartrate Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 230000004132 lipogenesis Effects 0.000 description 1
• XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
• 229910052808 lithium carbonate Inorganic materials 0.000 description 1
• 229910000103 lithium hydride Inorganic materials 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 229960004391 lorazepam Drugs 0.000 description 1
• DLPASUVGCQPFFO-UHFFFAOYSA-N magnesium;ethane Chemical compound [Mg+2].[CH2-]C.[CH2-]C DLPASUVGCQPFFO-UHFFFAOYSA-N 0.000 description 1
• FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
• RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
• 206010025482 malaise Diseases 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 229960004090 maprotiline Drugs 0.000 description 1
• QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
• 210000004086 maxillary sinus Anatomy 0.000 description 1
• 229960000299 mazindol Drugs 0.000 description 1
• 230000007721 medicinal effect Effects 0.000 description 1
• 229940051129 meperidine hydrochloride Drugs 0.000 description 1
• MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 1
• CDGNLUSBENXDGG-UHFFFAOYSA-N meta-Cresidine Chemical compound COC1=CC=C(N)C(C)=C1 CDGNLUSBENXDGG-UHFFFAOYSA-N 0.000 description 1
• 229960001797 methadone Drugs 0.000 description 1
• FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
• 229960005189 methadone hydrochloride Drugs 0.000 description 1
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
• IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
• ITYJDNHFRZSTJY-UHFFFAOYSA-N methanesulfonyl bromide Chemical compound CS(Br)(=O)=O ITYJDNHFRZSTJY-UHFFFAOYSA-N 0.000 description 1
• WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• MFBAJTMHHZXUCK-UHFFFAOYSA-N methyl 2-bromoethaneperoxoate Chemical compound COOC(=O)CBr MFBAJTMHHZXUCK-UHFFFAOYSA-N 0.000 description 1
• XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
• LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
• FMXOEQQPVONPBU-UHFFFAOYSA-N methylidene(dioxido)azanium Chemical compound [O-][N+]([O-])=C FMXOEQQPVONPBU-UHFFFAOYSA-N 0.000 description 1
• CSHCPECZJIEGJF-UHFFFAOYSA-N methyltin Chemical compound [Sn]C CSHCPECZJIEGJF-UHFFFAOYSA-N 0.000 description 1
• TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
• 229960004503 metoclopramide Drugs 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
• 229960004644 moclobemide Drugs 0.000 description 1
• VDCLSGXZVUDARN-UHFFFAOYSA-N molecular bromine;pyridine;hydrobromide Chemical compound Br.BrBr.C1=CC=NC=C1 VDCLSGXZVUDARN-UHFFFAOYSA-N 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 229960005195 morphine hydrochloride Drugs 0.000 description 1
• XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
• 229960004715 morphine sulfate Drugs 0.000 description 1
• GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
• 229960003066 morphine tartrate Drugs 0.000 description 1
• 201000003152 motion sickness Diseases 0.000 description 1
• 208000013465 muscle pain Diseases 0.000 description 1
• TVKQNLJAPCZTNZ-UHFFFAOYSA-N n-(furan-3-ylmethyl)-2-phenylpiperidin-3-amine Chemical compound C1=COC=C1CNC1CCCNC1C1=CC=CC=C1 TVKQNLJAPCZTNZ-UHFFFAOYSA-N 0.000 description 1
• FWURKORMEVOPIB-UHFFFAOYSA-N n-[[3-(2,3-dihydro-1h-inden-2-yloxy)-4-methoxyphenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound C1=C(OC2CC3=CC=CC=C3C2)C(OC)=CC=C1CNC1CCCNC1C1=CC=CC=C1 FWURKORMEVOPIB-UHFFFAOYSA-N 0.000 description 1
• QAUMOPFHQITQBI-UHFFFAOYSA-N n-[[3-(4-methoxyphenoxy)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound C1=CC(OC)=CC=C1OC1=CC=CC(CNC2C(NCCC2)C=2C=CC=CC=2)=C1 QAUMOPFHQITQBI-UHFFFAOYSA-N 0.000 description 1
• ZWRDBWDXRLPESY-UHFFFAOYSA-N n-benzyl-n-ethylethanamine Chemical compound CCN(CC)CC1=CC=CC=C1 ZWRDBWDXRLPESY-UHFFFAOYSA-N 0.000 description 1
• SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 1
• 229960000805 nalbuphine Drugs 0.000 description 1
• 229960001513 nalbuphine hydrochloride Drugs 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
• UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
• 229960005254 naratriptan Drugs 0.000 description 1
• VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
• 229960001800 nefazodone Drugs 0.000 description 1
• 208000019382 nerve compression syndrome Diseases 0.000 description 1
• 239000000181 nicotinic agonist Substances 0.000 description 1
• 125000004971 nitroalkyl group Chemical group 0.000 description 1
• 230000000422 nocturnal effect Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
• 229960001158 nortriptyline Drugs 0.000 description 1
• 239000012038 nucleophile Substances 0.000 description 1
• 229960005343 ondansetron Drugs 0.000 description 1
• 238000005580 one pot reaction Methods 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 125000002524 organometallic group Chemical group 0.000 description 1
• ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
• 229960004535 oxazepam Drugs 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 229960005118 oxymorphone Drugs 0.000 description 1
• 229960005374 oxymorphone hydrochloride Drugs 0.000 description 1
• MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 229960005301 pentazocine Drugs 0.000 description 1
• VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
• OQGYMIIFOSJQSF-DTOXXUQYSA-N pentazocine hcl Chemical compound Cl.C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 OQGYMIIFOSJQSF-DTOXXUQYSA-N 0.000 description 1
• 229960003809 pentazocine hydrochloride Drugs 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 208000030062 persistent idiopathic facial pain Diseases 0.000 description 1
• 229960000482 pethidine Drugs 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 229960000964 phenelzine Drugs 0.000 description 1
• AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
• 239000003600 podophyllotoxin derivative Substances 0.000 description 1
• 206010036067 polydipsia Diseases 0.000 description 1
• 229920000137 polyphosphoric acid Polymers 0.000 description 1
• 235000011056 potassium acetate Nutrition 0.000 description 1
• CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
• VLYFRFHWUBBLRR-UHFFFAOYSA-L potassium;sodium;carbonate Chemical compound [Na+].[K+].[O-]C([O-])=O VLYFRFHWUBBLRR-UHFFFAOYSA-L 0.000 description 1
• 229960004856 prazepam Drugs 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 229940065347 propoxyphene hydrochloride Drugs 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 239000003586 protic polar solvent Substances 0.000 description 1
• 229960002601 protriptyline Drugs 0.000 description 1
• BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
• 239000000649 purine antagonist Substances 0.000 description 1
• BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 description 1
• AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
• QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
• 150000003222 pyridines Chemical class 0.000 description 1
• 239000003790 pyrimidine antagonist Substances 0.000 description 1
• 238000010526 radical polymerization reaction Methods 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 1
• 229960000425 rizatriptan Drugs 0.000 description 1
• HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
• 229950005741 rolipram Drugs 0.000 description 1
• UAWABSHMGXMCRK-UHFFFAOYSA-L samarium(ii) iodide Chemical compound I[Sm]I UAWABSHMGXMCRK-UHFFFAOYSA-L 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
• MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
• 229960003946 selegiline Drugs 0.000 description 1
• 239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 description 1
• 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
• 239000010802 sludge Substances 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 229910001023 sodium amalgam Inorganic materials 0.000 description 1
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 238000011916 stereoselective reduction Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 239000003890 substance P antagonist Substances 0.000 description 1
• 125000003107 substituted aryl group Chemical group 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
• 229960004739 sufentanil Drugs 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 150000003460 sulfonic acids Chemical class 0.000 description 1
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
• 229960000894 sulindac Drugs 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
• 229960003708 sumatriptan Drugs 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 239000002462 tachykinin receptor antagonist Substances 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• DRDVJQOGFWAVLH-UHFFFAOYSA-N tert-butyl n-hydroxycarbamate Chemical compound CC(C)(C)OC(=O)NO DRDVJQOGFWAVLH-UHFFFAOYSA-N 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 238000007280 thionation reaction Methods 0.000 description 1
• 238000003354 tissue distribution assay Methods 0.000 description 1
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
• 229960003991 trazodone Drugs 0.000 description 1
• 229960005294 triamcinolone Drugs 0.000 description 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
• 229960002117 triamcinolone acetonide Drugs 0.000 description 1
• YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
• SYUVAXDZVWPKSI-UHFFFAOYSA-N tributyl(phenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC=C1 SYUVAXDZVWPKSI-UHFFFAOYSA-N 0.000 description 1
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
• WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 1
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
• COHOGNZHAUOXPA-UHFFFAOYSA-N trimethyl(phenyl)stannane Chemical compound C[Sn](C)(C)C1=CC=CC=C1 COHOGNZHAUOXPA-UHFFFAOYSA-N 0.000 description 1
• OWUGVJBQKGQQKJ-UHFFFAOYSA-M trimethylsulfanium;chloride Chemical compound [Cl-].C[S+](C)C OWUGVJBQKGQQKJ-UHFFFAOYSA-M 0.000 description 1
• 229960002431 trimipramine Drugs 0.000 description 1
• ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• 229960004688 venlafaxine Drugs 0.000 description 1
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
• 208000027491 vestibular disease Diseases 0.000 description 1
• 210000001213 vestibule labyrinth Anatomy 0.000 description 1
• 229960001255 viloxazine Drugs 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• PGOLTJPQCISRTO-UHFFFAOYSA-N vinyllithium Chemical compound [Li]C=C PGOLTJPQCISRTO-UHFFFAOYSA-N 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 208000009935 visceral pain Diseases 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• 235000005074 zinc chloride Nutrition 0.000 description 1
• QGDIJZMKEQCRBX-UHFFFAOYSA-N zinc;ethene Chemical compound [Zn+2].[CH-]=C.[CH-]=C QGDIJZMKEQCRBX-UHFFFAOYSA-N 0.000 description 1